



## OPEN ACCESS

# Mechanisms and therapeutic effectiveness of lactobacilli

Alessandro Di Cerbo,<sup>1</sup> Beniamino Palmieri,<sup>2</sup> Maria Aponte,<sup>3</sup>  
Julio Cesar Morales-Medina,<sup>4</sup> Tommaso Iannitti<sup>5</sup>

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/jclinpath-2015-202976>).

<sup>1</sup>School of Specialization in Clinical Biochemistry, "G. d'Annunzio" University, Chieti, Italy

<sup>2</sup>Department of General Surgery and Surgical Specialties, University of Modena and Reggio Emilia Medical School, Surgical Clinic, Modena, Italy

<sup>3</sup>Department of Agriculture, University of Naples "Federico II", Portici, Naples, Italy

<sup>4</sup>Centro de Investigación en Reproducción Animal, CINVESTAV- Universidad Autónoma de Tlaxcala, Tlaxcala, México

<sup>5</sup>Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK

## Correspondence to

Dr Tommaso Iannitti, Sheffield Institute for Translational Neuroscience, University of Sheffield, 385A Glossop Road, Sheffield, S10 2HQ, UK; [tommaso.iannitti@gmail.com](mailto:tommaso.iannitti@gmail.com)

Received 25 February 2015

Revised 2 September 2015

Accepted 14 September 2015

## ABSTRACT

The gut microbiome is not a silent ecosystem but exerts several physiological and immunological functions. For many decades, lactobacilli have been used as an effective therapy for treatment of several pathological conditions displaying an overall positive safety profile. This review summarises the mechanisms and clinical evidence supporting therapeutic efficacy of lactobacilli. We searched Pubmed/Medline using the keyword '*Lactobacillus*'. Selected papers from 1950 to 2015 were chosen on the basis of their content. Relevant clinical and experimental articles using lactobacilli as therapeutic agents have been included. Applications of lactobacilli include kidney support for renal insufficiency, pancreas health, management of metabolic imbalance, and cancer treatment and prevention. In vitro and in vivo investigations have shown that prolonged lactobacilli administration induces qualitative and quantitative modifications in the human gastrointestinal microbial ecosystem with encouraging perspectives in counteracting pathology-associated physiological and immunological changes. Few studies have highlighted the risk of translocation with subsequent sepsis and bacteraemia following probiotic administration but there is still a lack of investigations on the dose effect of these compounds. Great care is thus required in the choice of the proper *Lactobacillus* species, their genetic stability and the translocation risk, mainly related to inflammatory disease-induced gut mucosa enhanced permeability. Finally, we need to determine the adequate amount of bacteria to be delivered in order to achieve the best clinical efficacy decreasing the risk of side effects.

## INTRODUCTION

The impact of the gastrointestinal (GI) tract on brain functions and behaviour including anxiety, mood, cognition and pain regulation has been recognised since the 19th century as Hipocrates' dictum stated "Let the food be thy medicine and medicine be thy food".<sup>1</sup> Therefore, the gut-brain axis has been proposed as a homeostatic route of communication using neuronal, hormonal and immunological pathways.<sup>1-3</sup> The GI tract, which is an active part of this axis, is harboured by approximately 100 trillion organisms, mainly anaerobes, which constitute the microbiome and exceed 10 times the overall number of cells present in the human body.<sup>4,5</sup> The microbiome plays a key role in the development and functionality of the innate and adaptive immune responses.<sup>1</sup> Among microbiome-composing organisms, lactobacilli can inhibit the growth of pathogenic bacteria and have

a favourable safety profile.<sup>6</sup> However, different species of the genus *Lactobacillus* (L.) can produce different particular responses in the host, and the effects exerted by some strains of the same species may not be beneficial.<sup>7</sup>

## AIM AND SEARCHING CRITERIA

In this review, we summarise the experimental and clinical evidence on lactobacilli by providing a comprehensive overview of their efficacy for treatment of numerous pathologies and outlining new therapeutic trends. We searched Pubmed/Medline using the keyword '*Lactobacillus*'. Selected papers from 1950 to 2015 were chosen on the basis of their content. Relevant clinical and experimental articles that used lactobacilli as therapeutic agents and written in English language have been included. Clinical findings organised by pathology are summarised in [tables 1-15](#).

## EXPERIMENTAL EVIDENCE

### Adhesion to the gastrointestinal mucosa

Dietary changes, antibiotic exposure and infections may cause dysbiosis, a perturbation of the microbiome-host symbiosis that favours the invasion and growth of pathogenic species to the detriment of health-promoting bacteria, including lactobacilli, within the GI tract.<sup>8,9</sup> Indeed, adhesion of lactobacilli to the host's GI tract, by means of an interaction with toll-like receptors, is of crucial importance due to its ability to trigger the host's immune response.<sup>10,11</sup> Nevertheless, adhesion to the GI tract can also be driven by surface proteins and fatty acids, as observed for *L. rhamnosus* PEN,<sup>12</sup> and proteinaceous surface layer components, as observed for *L. plantarum* 91.<sup>13</sup> Therefore, the ability of lactobacilli to adhere and colonise the GI tract mucosa has been investigated in the clinical setting and is summarised in [table 1](#).<sup>14-17</sup>

### Antitumour activity

Intestinal bacteria produce mutagens such as deoxycholic acid from primary bile acids or by enzymatic conversion when foreign compounds, such as nitroaromatics, azo compounds and nitrates, are ingested.<sup>18</sup> Lactobacilli are capable of competitively inhibiting carcinogen and mutagen formation, altering overall metabolism, adsorbing and removing toxic and mutagenic metabolites and producing protective metabolites.<sup>19</sup> In the context of colorectal cancer, the prevention mechanism exerted by probiotics may be a combination of different actions such as intestinal microbiota modification,<sup>20-26</sup> inactivation of cancerogenic

**To cite:** Di Cerbo A, Palmieri B, Aponte M, et al. *J Clin Pathol* Published Online First: [please include Day Month Year] doi:10.1136/jclinpath-2015-202976

**Table 1** Lactobacilli displaying ability to adhere to the gastrointestinal tract mucosa

Bacteria	Dose	Ref. (Design)
<i>L. gasseri</i> SBT2055SR	10 <sup>11</sup> CFU	<sup>14</sup> (open study)
<i>L. reuteri</i> DSM 12246	10 <sup>10</sup> CFU (of each)	<sup>17</sup> (double-blind cross-over study)
<i>L. rhamnosus</i> 19070-2		
<i>L. rhamnosus</i> LGG		
<i>L. acidophilus</i> 821-3	1×10 <sup>10</sup> CFU	<sup>15</sup> (open study)
<i>L. rhamnosus</i> 19070-2	1×10 <sup>10</sup> CFU (of each)	<sup>16</sup> (open study)
<i>L. reuteri</i> DSM 12246		

compounds,<sup>27–35</sup> competition with putrefactive and pathogenic microbiota,<sup>36–40</sup> improvement of the host's immune response,<sup>41–55</sup> enhancement of natural killer cell cytotoxicity<sup>56</sup> and inhibition of interleukin (IL) 6 production in the colonic mucosa<sup>57</sup> counteracting cancer development by antiproliferative effects<sup>58</sup> via regulation of apoptosis and cell differentiation,<sup>59–67</sup> fermentation of undigested food<sup>68–73</sup> and inhibition of tyrosine kinase signalling pathways.<sup>74</sup> Experimental studies have also shown that lactobacilli contained in dietary supplements and fermented food, such as yogurt heat-killed *L. casei* strain Shirota (LC 9018)<sup>54</sup> reduce colon cancer risk.<sup>75–77</sup> These activities have been ascribed to the alteration of gut microbiota and, subsequently, to the inhibition or the induction of colonic enzymes controlling the growth of harmful bacteria, improving immune function and stimulating the production of metabolites possessing antitumour activity. Clinical studies showing efficacy of lactobacilli for treatment of cancer have been summarised in table 2.

### Antitoxic activity

Lactobacilli display detoxifying properties and their ability to neutralise toxins<sup>81</sup> or toxic compounds<sup>82</sup> is important to maintain the host's health. For instance, *L. reuteri* CRL 1098 and *L. acidophilus* CRL 1014 showed the ability to enhance tumour necrosis factor (TNF)-α response to ochratoxin A, a widespread mycotoxin from *Aspergillus* and *Penicillium* species. This mycotoxin can contaminate food products<sup>83</sup> and induce hepatotoxicity, nephrotoxicity and immunotoxicity,<sup>84</sup> thus increasing TNF-α production and diminishing toxin-induced apoptosis.<sup>83</sup> Individual treatment with *L. plantarum* 2017 405, *L. fermentum* 353, *L. acidophilus* DSM 21007 and *L. rhamnosus* GG antagonised *C. difficile* isolated from faecal specimens from adult patients affected by diarrhoea, as observed by measurement of the inhibition zone.<sup>85</sup> Another *L.* strain, *L. reuteri* RC-14,<sup>86</sup> produced small signalling molecules able to interfere with a key

regulator of virulence genes, *agr*. Additionally, *L. reuteri* RC-14 repressed the expression of toxic shock syndrome toxin-1 in menstrual toxic shock syndrome induced by *Staphylococcus* (*S.*) *aureus* strains. Quantitative real-time polymerase chain reaction (PCR) data revealed that transcription from the toxic shock *tst* promoter was strongly inhibited in culture supernatant in presence of *L. reuteri* RC-14. Moreover, a transcriptional level alteration of virulence-associated regulators was observed, providing a unique mechanism by which endogenous or exogenous lactobacilli can attenuate production of virulence factors. This study highlighted the existence of a crosstalk mechanism between two distinct bacterial signalling systems, alteration in the transcriptional levels of virulence-associated regulators *sarA* and *saeRS* and transcription inhibition from *Ptst*, P2 and P3 promoters, providing a potential defensive mechanism against *S. aureus* infections. Therefore, administration of well-characterised lactobacilli can be helpful to overcome antibiotic-related complications, such as antibiotic resistance. Based on 16SrDNA sequences and non-coding fragments characterisation of different lactobacilli, Fei and coworkers reported a significantly high nitrite degradation capacity exerted by *L. sp* DMDL 9010 after a 24 h fermentation in the medium.<sup>87</sup> Compound degradation activity of lactobacilli has also been observed for cadmium after high dietary exposure.<sup>88</sup> In this regard, two *L. kefir* strains, CIDCA 8348 and JCM 5818, can remove cadmium cations when cocultured with a human hepatoma cell line, HepG2.<sup>89</sup> Particularly, *L. kefir* JCM 5818 is more efficient in protecting cells from cadmium toxicity. Therefore, since consumption of harmful metals is a growing medical issue, the regular administration of formulations containing the above mentioned strains might be useful to prevent toxin compound-induced lipid peroxidation and free radical production.

### Vaginal colonisation

Vaginal microbiota is dominated by lactobacilli.<sup>90</sup> When the balance among bacterial species within this environment is altered, antibacterial defense mechanisms lose their efficacy leading to pathogenic bacteria proliferation.<sup>90</sup> For instance, reduction in the number of vaginal lactobacilli and their antimicrobial properties (such as lysostaphin expression in order to cleave the cell wall of *S. aureus* thus inhibiting its growth),<sup>91</sup> and H<sub>2</sub>O<sub>2</sub> production,<sup>92</sup> cause bacterial vaginosis, the most common symptomatic microbial imbalance.<sup>93</sup> In patients affected by bacterial vaginosis, lactobacilli are replaced by *Gardnerella vaginalis*,<sup>92–94</sup> *Candida* (*C.*) *albicans*,<sup>95</sup> *S. aureus*,<sup>91–96</sup> *Neisseria gonorrhoeae*<sup>40</sup> or other anaerobic bacteria. Uncontrolled growth of anaerobic bacteria such as *C. albicans* and subsequent vaginal colonisation may lead to

**Table 2** Clinical studies showing efficacy of lactobacilli for treatment of cancer

Bacteria	Dose	Pathology	Ref. (Design)
<i>B. lactis</i> Bb12 <i>L. rhamnosus</i> GG + Oligofructose enriched inulin (SYN1)	1×10 <sup>10</sup> CFU (total)	Colon cancer	<sup>39</sup> (randomised, double-blind, placebo-controlled study)
<i>L. rhamnosus</i> LC705 <i>P. freudenreichii</i> subsp <i>Shermanii</i>	12 g 2–5×10 <sup>10</sup> CFU (of each)	Liver cancer	<sup>78</sup> (randomised, double-blind, placebo-controlled study)
<i>B. longum</i> <i>L. acidophilus</i> <i>E. faecalis</i>	10 <sup>8</sup> CFU/g (0.21 g) (total)	Colorectal cancer	<sup>79</sup> (open study)
<i>B. natto</i> <i>L. acidophilus</i>	10 mg 30 mg	Colorectal cancer	<sup>80</sup> (open study)

**Table 3** Clinical studies of lactobacilli showing efficacy for treatment of vaginal disorders

Bacteria	Dose	Pathology	Ref. (Design)
<i>L. plantarum</i> P17630	>10 <sup>8</sup> CFU	Acute vulvovaginal candidiasis	<sup>97</sup> (retrospective comparative study)
<i>L. rhamnosus</i> GR-1	>10 <sup>9</sup> CFU (of each)	Potential pathogenic bacteria and yeast vagina colonisation	<sup>102</sup> (open study)
<i>L. fermentum</i> RC-14			
Kramegin® ( <i>L. acidophilus</i> )	Not stated	Abnormal cervical cytology	<sup>103</sup> (open study)
+ lactic acid and Krameria triandra extract)			
Ellen AB® ( <i>L. gasseri</i> LN40, <i>L. fermentum</i> LN99, <i>L. casei</i> subsp <i>rhamnosus</i> LN113 and <i>P. acidilactici</i> LN23	10 <sup>8–10</sup> CFU (total)	Bacterial vaginosis and vulvovaginal candidiasis	<sup>104</sup> (randomised double-blind placebo-controlled study)
+ an inert carrying matrix of maltodextrin and magnesium stearate)	Not stated		
<i>L. fermentum</i> LF10	0.4×10 <sup>9</sup> CFU (of each)	Recurrent vulvovaginal candidiasis	<sup>105</sup> (clinical study)
<i>L. acidophilus</i> LA02			
+ Arabinogalactan	340 mg		
+ Fructooligosaccharides	241 mg		
<i>L. fermentum</i> LF15	0.4×10 <sup>9</sup> CFU (of each)	Bacterial vaginosis	<sup>106</sup> (pilot study)
<i>L. plantarum</i> LP01			
+ Tara gum	50 mg		
Florisia® ( <i>L. brevis</i> (CD2), <i>L. salivarius</i> subsp <i>salicinius</i> (FV2) and <i>L. plantarum</i> (FV9))	10 <sup>9</sup> CFU (total)	Bacterial vaginosis	<sup>107</sup> (randomised, double-blind, placebo-controlled study)
<i>L. rhamnosus</i> GR-1	2.5×10 <sup>9</sup> CFU (of each)	Vaginal flora overgrowth	<sup>108</sup> (randomised, double-blind, placebo-controlled study)
<i>L. reuteri</i> RC-14			<sup>109</sup> (double-blind, randomised, placebo-controlled study)
EcoVag® ( <i>L. gasseri</i> (Lba EB01-DSM 14869) and <i>L. Rhamnosus</i> (Lbp PB01-DSM 14870))	10 <sup>8–9</sup> CFU (of each)	Bacterial vaginosis	

vulvovaginal candidiasis,<sup>97</sup> which is estimated to occur at least once during the lifetime of 75% of the female population.<sup>98</sup> Vaginal microbial imbalance may also represent an important risk factor for increased risk of urinary tract infections and pregnancy complications, such as endometritis, chorioamnionitis, preterm birth and intrauterine death.<sup>99</sup> Intravaginal colonisation by bacterial strains with high haemolytic activity and pigment production [eg, group B streptococci (GBS)] is one of the most important risk factors for disease development in newborns.<sup>100</sup> Therefore, a murine model was proposed to determine if *L. reuteri* CRL1324 would exert a preventive effect on vaginal colonisation by *Streptococcus* (*St.*) *agalactiae* NH17.<sup>100</sup> Following *L. reuteri* CRL1324 administration, a reduced leucocyte influx induced by *St. agalactiae* NH17 and a preventive effect on its vaginal colonisation were observed prior to the GBS challenge. Although GBS colonization occurs in up to 50–70% of neonates born from colonized mothers,<sup>101</sup> the introduction of new antimicrobial agents, such as *L. reuteri* CRL1324, could be considered a valuable and safer alternative to antibiotics to reduce infections caused by GBS. Clinical studies of lactobacilli showing efficacy for treatment of vaginal disorders have been summarised in table 3.

### Cholesterol-lowering activity

There is an increasing demand for non-pharmacological therapies to improve cholesterol profile due to the cost and side effects associated with available pharmacological treatments for cholesterol-related diseases. Hence great attention has been given to lactobacilli due to their effectiveness in modulating lipid metabolism reducing statin requirement (statins inhibit the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase that

produces about 70% of the total body cholesterol)<sup>110 111</sup> and serum cholesterol level by means of bile salt hydrolase that has a direct impact on the host's bile salt metabolism accounting for the formation of deconjugated bile acids.<sup>112</sup> Furthermore, cholesterol-reducing properties were also observed for *L. oris* HMI118, HMI28, HMI43, HMI68 and HMI74 isolated from breast milk.<sup>113</sup> Although all the tested strains assimilated cholesterol even in the absence of bile salts, surviving in the acidic conditions of the intestine and tolerating high bile concentrations, *L. oris* HMI68 showed the highest cholesterol assimilation deconjugating sodium glycocholate (the most predominant bile salt in the human intestine) and sodium taurocholate.

**Table 4** Clinical studies of lactobacilli showing efficacy for treatment of hypercholesterolaemia

Bacteria	Dose	Ref. (Design)
<i>L. plantarum</i> CECT 7527 CECT 7528 CECT 7529	1.2×10 <sup>9</sup> CFU (total)	<sup>118</sup> (controlled, randomised, double-blind study)
<i>L. acidophilus</i> L1	Not stated	<sup>119</sup> (double-blind, placebo-controlled, cross-over study)
<i>L. reuteri</i> NCIMB 30242	5×10 <sup>9</sup> CFU	<sup>120</sup> (double-blind, placebo-controlled, randomised, parallel-arm, multicentre study)
<i>L. acidophilus</i>	Not stated	<sup>121</sup> (single-blind and randomised cross-over study)
<i>B. lactis</i>	Not stated	

**Table 5** Clinical studies of lactobacilli showing inhibitory activity against *H. pylori* infection

Bacteria	Dose	Pathology	Ref. (Design)
<i>L. johnsonii</i> La1	> 10 <sup>7</sup> CFU/mL (80 mL)	Asymptomatic <i>H. pylori</i> infection	<sup>173</sup> (double-blind, randomised, controlled clinical study)
<i>L. gasseri</i> OLL2716	1–1.4×10 <sup>7</sup> CFU/g (90 g)	<i>H. pylori</i> infection	<sup>174</sup> (open study)
Enterolactis® ( <i>L. casei</i> subsp <i>casei</i> DG + Vitamin B1, B2 and B6)	1.6×10 <sup>9</sup> CFU	<i>H. pylori</i> infection	<sup>182</sup> (open study)
Actimel®: ( <i>L. acidophilus</i> HY2177, <i>L. casei</i> HY2743, <i>B. longum</i> HY8001 and <i>St.</i> <i>thermophilus</i> B-1)	5×10 <sup>9</sup> CFU (total)	<i>H. pylori</i> infection	<sup>184</sup> (open study)
<i>L. reuteri</i> ATCC 55730	1×10 <sup>8</sup> CFU	<i>H. pylori</i> infection	<sup>185</sup> (open study)
Will yogurt ( <i>L. acidophilus</i> HY2177, <i>L. casei</i> HY2743, <i>B. longum</i> HY8001 and <i>St. thermophilus</i> B-1)	≥1×10 <sup>5</sup> CFU ≥1×10 <sup>5</sup> CFU ≥1×10 <sup>6</sup> CFU ≥1×10 <sup>8</sup> CFU	<i>H. pylori</i> infection	<sup>186</sup> (randomised triple-therapy study)
AB-yogurt ( <i>L. acidophilus</i> La5 and <i>B. lactis</i> Bb12)	10 <sup>7</sup> CFU/mL (230 mL) (of each)	<i>H. pylori</i> infection	<sup>175</sup> (open study)
Genefilus F19® ( <i>L. paracasei</i> sub. <i>paracasei</i> F19)	12×10 <sup>9</sup> CFU	<i>H. pylori</i> infection-related gastroesophageal reflux	<sup>177</sup> (randomised, double-blind, placebo-controlled study)
<i>L. reuteri</i> Gastrus ( <i>L. reuteri</i> DSM 17938 and <i>L. reuteri</i> ATCC PTA 6475)	1×10 <sup>8</sup> CFU (total)	<i>H. pylori</i> infection	<sup>187</sup> (prospective, double-blind, randomised, placebo-controlled study)
<i>L. gasseri</i> OLL2716	≥10 <sup>9</sup> CFU	<i>H. pylori</i> infection	<sup>188</sup> (randomised, controlled clinical study)
<i>L. brevis</i> CD2	20×10 <sup>9</sup> CFU	<i>H. pylori</i> infection	<sup>189</sup> (open study)

Cholesterol assimilation has also been evaluated as a possible therapeutic approach to reduce the risk for cardiovascular diseases.<sup>114</sup> In this regard, Tomaro-Duchesneau and coworkers investigated the ability of 11 *L.* strains (*L. reuteri* NCIMB 11951, 701359, 702655, 701089 and 702656, *L. fermentum* NCIMB 5221, 8829, 2797, *L. rhamnosus* ATCC 53103 GG, *L. acidophilus* ATCC 314 and *L. plantarum* ATCC 14917) to assimilate cholesterol. While *L. plantarum* ATCC 14917 was the best cholesterol assimilator in de Man, Rogosa and Sharpe broth, *L. reuteri* NCIMB 701089 assimilated over 67% of cholesterol under physiological intestinal conditions. The hypocholesterolaemic effect of all strains, particularly of *L. reuteri* NCIMB 701089, was linked to intrinsic bile salt hydrolase activity, assimilation and incorporation in cellular membranes and compound production, for example, ferulic acid,<sup>115</sup> able to inhibit the activity of enzymes, including 3-hydroxy-3-methylglutaryl-coenzyme A reductase.<sup>116</sup> More recently, cholesterol-reducing *L.* spp. GI6, GI9, GI11 and GI15 were also isolated from traditionally fermented south Indian koozh and gherkin (a variety of cucumber).<sup>117</sup> *L.* GI9 was able to survive at pH 2.0 and 0.50% bile salt for 3 h without losing its viability also exhibiting the maximum cholesterol reduction. Nevertheless, all tested lactobacilli exhibited inhibitory activity against several pathogens including *Escherichia coli* MTCC

1089, *Pseudomonas (P.) aeruginosa* MTCC 2642, *S. aureus* MTCC 7443, *Klebsiella (K.) pneumoniae* MTCC 7028, *Bacillus subtilis* MTCC 8561 and *C. albicans* BS3 and were able to deconjugate bile salts. Clinical studies of lactobacilli showing efficacy for treatment of hypercholesterolaemia have been summarised in table 4.

### Antioxidant activity

Lactobacilli can prevent lipid peroxidation<sup>122</sup> and free oxygen radical production<sup>123</sup> due to their ability to create the low oxidation-reduction potential required for their optimal growth.<sup>124</sup> Amaretti and coworkers combined the strains *Bifidobacterium (B.) animalis* subsp *lactis* DSMZ 23032, *L. acidophilus* DSMZ 23033 and *L. brevis* DSMZ 23034 and administered them for 18 days to rats previously treated with doxorubicin, an anthracycline antibiotic.<sup>125</sup> Analysis of plasma antioxidant activity, glutathione concentration, as well as levels of reactive oxygen species, revealed a reduction in doxorubicin-induced oxidative stress, thus supporting antioxidant activity of these probiotics.

### Antibacterial and antiviral activity

Probiotic strains beneficially affect the host by replacing pathogenic bacteria in the GI tract and modulating immune responses.<sup>126</sup> Experimental studies have shown that lactobacilli, which can adhere to enterocytes, are effective in preventing the enteropathogen-mediated infection by competing for nutrients<sup>127</sup> and binding sites (eg, inducing intestinal mucin gene expression),<sup>128–132</sup> by secreting antimicrobial substances<sup>133</sup> such as organic acids,<sup>134–142</sup> bacteriocins<sup>143–145</sup> and hydrogen peroxide<sup>146–152</sup> and eventually by counteracting the spread within the colonised body,<sup>153–155</sup> reducing gut pH<sup>133 141 156</sup> and producing biosurfactants.<sup>157–159</sup> As far as bacterial activity is concerned, *L. plantarum* GK81, *L. acidophilus* GK20 and *L. plantarum* JSA22 inhibit *Salmonella* spp infection in intestinal epithelial

**Table 6** Clinical studies of lactobacilli showing efficacy for treatment of oxaluria

Bacteria	Dose	Ref. (Design)
<i>L. acidophilus</i> <i>L. plantarum</i> <i>St. thermophilus</i> <i>B. infantis</i> <i>L. brevis</i> (CD2)	8×10 <sup>11</sup> CFU (of each)	<sup>197</sup> (open study)



**Table 7** Clinical studies of lactobacilli showing efficacy for treatment of mastitis

Bacteria	Dose	Pathology	Ref. (Design)
<i>L. fermentum</i> CECT5716 <i>L. salivarius</i> CECT5713	1×10 <sup>9</sup> CFU (of each)	Infectious mastitis induced by <i>S. epidermidis</i> or <i>S. aureus</i>	<sup>202</sup> (open study)
<i>L. salivarius</i> CECT5713 and <i>L. gasseri</i> CECT5714 + a matrix of methylcellulose	1×10 <sup>10</sup> CFU (of each)  Not stated	Mastitis induced by <i>S. epidermidis</i> or <i>S. aureus</i>	<sup>203</sup> (open study)

cells<sup>160 161</sup> and *L. acidophilus* strain inhibits various pathogenic bacteria including *P. aeruginosa*, *E. coli*, *Enterobacter* and *K. spp.*<sup>150</sup> With reference to antiviral activity, lactobacilli harbour surface layer proteins involved in the enhancement of viral entry.<sup>162</sup> Moreover, increasing data indicate that abnormal vaginal flora lacking lactobacilli can facilitate viral sexually transmitted disease diffusion such as in the case of HIV,<sup>163</sup> human papilloma virus<sup>164</sup> and herpes simplex virus 2.<sup>165</sup> In this context, lactobacilli can exert an important role protecting the vaginal environment and reducing the risk of virus transmission.

### Helicobacter pylori infection

*Helicobacter (H.) pylori*, a gram-negative microaerophilic human gastric pathogen, is the main cause of chronic gastritis, gastric cancer and peptic ulcer disease.<sup>166</sup> Antibiotic treatment for *H. pylori* infection is associated with serious side effects and therefore there is an increasing demand for new treatments. Lactobacilli<sup>167 168</sup> have been extensively investigated for treatment of *H. pylori* infections. Numerous *L.* strains, that is, *L. gasseri* Chen, *L. plantarum* 18,<sup>167</sup> *L. gasseri* OLL2716,<sup>168</sup> *L. reuteri*,<sup>169</sup> *L. rhamnosus* GG, *L. rhamnosus* LC705, *Propionibacterium (P.) freudenreichii* subsp *shermanii* Js,<sup>170</sup> *L. delbrueckii* subsp *bulgaricus* 48, 144 and GB,<sup>171</sup> *L. rhamnosus* LC705, *P. freudenreichii* ssp *shermanii* Js,<sup>168</sup> *L. acidophilus* LB,<sup>172</sup> *L. plantarum* MLBPL1, *L. rhamnosus* GG and *L. lactis*<sup>137</sup> possess a neutralising activity against *H. pylori*. The same activity was also observed for heat-killed *L. johnsonii* Lal and *L. helveticus*<sup>173</sup> as well as for *L. gasseri* OLL2716,<sup>174</sup> as measured by <sup>13</sup>C-urea breath test. The suppressive effect of lactobacilli on *H. pylori* infection in vivo and in vitro has been reviewed.<sup>175–177</sup> For instance, *L. johnsonii* 1088 suppressed gastric acid secretion in mice via decreasing the number of gastrin-positive cells in the stomach.<sup>176</sup> Therefore *L. johnsonii* 1088 can be considered a valid add-on therapy to the gold standard treatment for *H. pylori* eradication consisting of a

proton pump inhibitor (PPI), amoxicillin and clarithromycin, and can also be used for prophylaxis of gastroesophageal reflux disease that can develop following *H. pylori* eradication. Nevertheless, the use of a PPI can also modify the gut microbiota causing dysbiosis.<sup>178–180</sup> In this regard, adding *L. paracasei* subsp *paracasei* F19 to triple therapy is a promising combination to counteract the effects of PPIs on intestinal dysbiosis.<sup>181</sup> Clinical studies of lactobacilli showing inhibitory activity against *H. pylori* infection have been summarised in table 5.

### Kidney disease

The last stage of chronic kidney disease induces an increase in plasma concentration of uraemic wastes and requires kidney transplantation or chronic dialysis.<sup>190</sup> Many studies support the probiotic approach as an alternative therapy for management of end-stage renal disease<sup>191</sup> and to relieve the 'uraemic' condition.<sup>189 192–194</sup> In particular, a high urease activity was observed for *S. spp.*, *L. casei*, *K. aerogenes* and *Enterococcus faecium* in the sheep rumen.<sup>192</sup> At the same time, the ability to degrade biogenic amines (BAs) was also assessed by Capozzi and coworkers.<sup>193</sup> They isolated two lactobacilli (*L. plantarum* NDT 09 and *L. plantarum* NDT 16) from wine and found that they were able to degrade tyramine (22.12%) and putrescine (31.09%), respectively. *L. casei* 4a and 5b, isolated from Zamorano cheese, also inhibited tyramine along with histamine, another BA.<sup>194</sup> However, BA degradation is not the only mechanism under investigation for treatment of end-stage renal disease and uraemic condition. The ability to degrade oxalate and to survive within the GI tract of a range of *B.* and *L.* species, isolated from the canine and feline GI tract, has also been evaluated. In vitro oxalate degradation was detected for 11 out of 18 *L.* strains (8 *L. animalis* and 3 *L. murinus*), but not for any of the *B.* strains.<sup>195</sup> Rats were fed on four selected strains (*L. animalis* 223C, *L. murinus* 1222, *L. animalis* 5323 and *L. murinus* 3133) for 4 weeks; urinary oxalate levels were

**Table 8** Clinical studies of lactobacilli showing immunomodulatory activity in various pathologies

Bacteria	Dose	Pathology	Ref. (Design)
<i>L. salivarius</i> LS01 <i>B. breve</i> BR03 + maltodextrin proBiotik®	1×10 <sup>9</sup> CFU (of each)  Not stated 2×10 <sup>9</sup> CFU (total)	Moderate/severe atopic dermatitis  Atopic dermatitis	<sup>223</sup> (randomised double-blinded active treatment vs placebo study)  <sup>207</sup> (double-blind, randomised, placebo-controlled study)
( <i>B. bifidum</i> , <i>L. acidophilus</i> , <i>L. casei</i> and <i>L. salivarius</i> )			
<i>L. pentosus</i> b240 Yakult®	2×10 <sup>10</sup> CFU 6.5×10 <sup>9</sup> CFU	Common cold Allergic rhinitis	<sup>224</sup> (randomised, double-blind, placebo-controlled study) <sup>210</sup> (double-blind, placebo-controlled study)
( <i>L. casei</i> Shirota)			
<i>L. paracasei</i> -33 <i>L. acidophilus</i> L-92	2×10 <sup>9</sup> CFU Not stated	Allergic rhinitis Atopic dermatitis	<sup>216</sup> (randomised, double-blind, placebo-controlled study) <sup>225</sup> (double-blind, randomised, clinical study)

**Table 9** Clinical studies of lactobacilli showing efficacy for treatment of gastrointestinal pathologies

Bacteria	Dose	Pathology	Ref. (Design)
VSL#3® ( <i>L. casei</i> , <i>L. plantarum</i> , <i>L. acidophilus</i> , <i>L. delbrueckii</i> subsp <i>bulgaricus</i> , <i>B. longum</i> , <i>B. breve</i> , <i>B. infantis</i> and <i>St. thermophilus</i> )	5×10 <sup>11</sup> CFU/g (3 g) (total)	Chronic pouchitis	<sup>230</sup> (open study)
Yakult® ( <i>L. casei</i> Shirota)	6.5×10 <sup>9</sup> CFU	Constipation	<sup>231</sup> (open study)
<i>L. plantarum</i> SN13T	2×10 <sup>8</sup> CFU	Constipation	<sup>232</sup> (double-blind, randomised study)
VSL#3® ( <i>L. casei</i> , <i>L. plantarum</i> , <i>L. acidophilus</i> , <i>L. delbrueckii</i> subsp <i>bulgaricus</i> , <i>B. longum</i> , <i>B. breve</i> , <i>B. infantis</i> and <i>St. thermophilus</i> )	5×10 <sup>11</sup> CFU/g (3 g) (total)	Ulcerative colitis	<sup>233</sup> (open study)

significantly reduced only in those rats fed on *L. animalis* 5323 and *L. animalis* 223C. Oxalate-degrading activity has also been assessed for other lactobacilli.<sup>196</sup> *L. paracasei* LPC09 displayed the highest oxalate-degrading activity converting 68.5% of ammonium oxalate followed by *L. gasseri* LGS01 (68.4%), *L. gasseri* LGS02 (66.2%), *L. acidophilus* LA07 (54.2%) and *L. acidophilus* LA02 (51.3%). The use of lactobacilli as agents able to integrate into the host's gut microbiota may thus be considered helpful in reducing oxaluria and preventing or decreasing the incidence and severity of kidney stone formation. Clinical studies of lactobacilli showing efficacy for treatment of oxaluria have been summarised in [table 6](#).

### Mastitis

Mastitis is an infectious inflammation of one or more breast lobules<sup>198</sup> with *S. aureus* and *S. epidermidis* being the most frequent aetiological agents<sup>199</sup> and with a prevalence of 3–33% among breastfeeding mothers.<sup>200</sup> Multidrug resistance and biofilm formation by pathogenic bacteria account for the lack of efficacy of antibiotics used for treatment of mastitis.<sup>201</sup> In this context, new strategies based on probiotics, as alternatives or complements to antibiotic therapy for the management of mastitis, are gaining a prominent role. Clinical studies of lactobacilli showing efficacy for treatment of mastitis have been summarised in [table 7](#).

### Immunomodulatory activity

Lactobacilli are potential adjuvants triggering mucosal and systemic immune responses.<sup>204</sup> The immunomodulatory effects of lactobacilli observed in various physiological systems include increased natural killer cell cytotoxicity<sup>205–206</sup> and induction of interferon-γ production<sup>205–213</sup> and cytokine expression.<sup>205–210</sup>

<sup>212–216</sup> In order to exert these immunomodulatory effects, lactobacilli must resist to digestive system processes<sup>217</sup> and adhere to the host's intestinal epithelium.<sup>218</sup> Lactobacilli (in particular *L. acidophilus*) can also be administered together with bifidobacteria in order to enhance the immune system.<sup>219–220</sup> This effect is accomplished by enhancing systemic/local immunity<sup>221</sup> and concurrently attenuating systemic stress response.<sup>222</sup> Clinical studies of lactobacilli showing immunomodulatory activity in various pathologies have been summarised in [table 8](#).

### Gastrointestinal pathologies

Even if the pathogenesis of irritable bowel syndrome (IBD) remains unknown, the luminal microbiome plays a key role in triggering and maintaining a balanced environment within the GI tract.<sup>226</sup> Dysbiosis may also play a key role in IBD.<sup>227</sup> Evidence from animal models<sup>228</sup> and clinical observations<sup>229</sup> outlined the putative therapeutic role of probiotic strains for IBD treatment. Restoring microbiota-host symbiosis can represent a promising approach for treatment of the above mentioned conditions and can be applied to other GI pathologies, as summarised in [table 9](#).

### Gastrointestinal tract survival

Strains belonging to *L.* and *B.* genera are the most studied in clinical practice.<sup>234</sup> The number of bacterial strains that reach the gut mucosa and colon, depends on several factors such as strain used, gastric transit survival,<sup>15–235</sup> and acid and bile tolerance.<sup>236</sup> Clinical studies of lactobacilli showing ability to survive in the GI tract have been summarised in [table 10](#).

**Table 10** Clinical studies of lactobacilli showing ability to survive in the gastrointestinal tract

Bacteria	Dose	Site	Ref. (Design)
<i>L. acidophilus</i> 821–3	1×10 <sup>10</sup> CFU	Gastrointestinal tract	<sup>15</sup> (open study)
<i>L. acidophilus</i>	1×10 <sup>8</sup> CFU/g (100 g)	Small intestine	<sup>237</sup> (open study)
<i>B. sp</i>	1×10 <sup>7</sup> CFU/g (100 g)		
<i>L. casei</i> Shirota	1×10 <sup>8</sup> CFU/mL (100 mL)	Gastrointestinal tract	<sup>238</sup> (14-day baseline, ingestion and follow-up periods)
<i>L. acidophilus</i> LA02 (DSM 21717)	5×10 <sup>9</sup> CFU (of each)	Gastrointestinal tract	<sup>239</sup> (double-blind, randomised, cross-over study)
<i>L. rhamnosus</i> LR04 (DSM 16605)			
<i>L. rhamnosus</i> GG (ATCC 53103)			
<i>L. rhamnosus</i> LR06 (DSM 21981)			
<i>B. lactis</i> BS01 (LMG P-21384)			
<i>L. plantarum</i> LP01 (LMG P-21021)	1×10 <sup>9</sup> CFU (of each)	Gastrointestinal tract	<sup>240</sup> (double-blind, randomised, cross-over study)
<i>B. breve</i> BR03 (DSM 16604)			
Lakcid® L ( <i>L. rhamnosus</i> 573/1, 573 U/2 and 573L3)	1.2×10 <sup>10</sup> CFU	Gastrointestinal tract	<sup>241</sup> (prospective, double-blinded, placebo-controlled randomised study)

**Table 11** Clinical studies of lactobacilli showing efficacy for treatment of diarrhoea

Bacteria	Dose	Pathology	Ref. (Design)
Actimel® ( <i>L. casei</i> DN 114001)	10 <sup>10</sup> CFU	Antibiotic-associated diarrhoea	<sup>249</sup> (observational study)
Balance™ ( <i>L. casei</i> , <i>L. rhamnosus</i> , <i>L. acidophilus</i> , <i>L. bulgaricus</i> , <i>B. strains</i> , <i>B. breve</i> , <i>B. longum</i> and <i>St. thermophilus</i> )	1×10 <sup>8</sup> CFU (total)	<i>H. pylori</i> infection-associated diarrhoea	<sup>250</sup> (randomised placebo-controlled triple-blind study)
<i>L. acidophilus</i> <i>L. rhamnosus</i> <i>B. bifidum</i> <i>B. longum</i> <i>E. faecium</i> +	2.5×10 <sup>9</sup> CFU (total)	Acute diarrhoea	<sup>251</sup> (prospective randomised, multicentre single-blinded clinical study)
fructo-oligosaccharide	625 mg		
<i>L. acidophilus</i> (CUL60, NCIMB 30157 and CUL21, NCIMB 30156), <i>B. bifidum</i> (CUL20, NCIMB 30153) and <i>B. lactis</i> (CUL34, NCIMB 30172)	6×10 <sup>10</sup> CFU (total)	Antibiotic-associated diarrhoea	<sup>252</sup> (prospective, parallel group study)
Probiotal ( <i>S. thermophilus</i> , <i>L. rhamnosus</i> , <i>L. acidophilus</i> , <i>B. lactis</i> and <i>B. infantis</i> +	6.5×10 <sup>9</sup> CFU (of each) 20 mg	Acute gastroenteritis	<sup>253</sup> (randomised, prospective placebo-controlled parallel clinical study)
Fructooligosaccharides +	1.2 mg		
Ascorbic acid)			
NAN 1® ( <i>L. acidophilus</i> , <i>L. rhamnosus</i> , <i>B. longum</i> and <i>S. boulardii</i> )	6.625×10 <sup>7</sup> CFU 3.625×10 <sup>7</sup> CFU 8.75×10 <sup>6</sup> CFU 1.375×10 <sup>7</sup> CFU	Acute rotavirus diarrhoea	<sup>254</sup> (prospective, double-blind, randomised study)
<i>L. rhamnosus</i> 35	6×10 <sup>8</sup> CFU	Acute rotaviral gastroenteritis	<sup>255</sup> (open-label randomised study)
<i>L. rhamnosus</i> (strains E/N, Oxy and Pen)	2×10 <sup>10</sup> CFU (of each)	Antibiotic-associated diarrhoea	<sup>256</sup> (double-blind, randomised, placebo-controlled study)
<i>L. acidophilus</i> LB +	10 <sup>9</sup> CFU	Non-rotavirus diarrhoea	<sup>257</sup> (randomised, double-blind, placebo-controlled clinical study)
spent culture medium	160 mg		
Lacid® L [ <i>L. rhamnosus</i> (573 L/1, 573 L/2 and 573 L/3)]	1.2×10 <sup>10</sup> CFU (total)	Infectious diarrhoea	<sup>258</sup> (randomised, double-blind, placebo-controlled study)
<i>L. paracasei</i> ST11	10 <sup>10</sup> CFU	Non-rotavirus diarrhoea	<sup>259</sup> (randomised, double-blind, placebo-controlled clinical study)
<i>L. casei</i> CERELA	10 <sup>11</sup> CFU/g (175 g) (of each)	Persistent diarrhoea	<sup>260</sup> (double-blind study)
<i>L. acidophilus</i> CERELA <i>S. boulardii</i> <i>L. rhamnosus</i> 19070–2 <i>L. reuteri</i> DSM 12246	10 <sup>10</sup> CFU (of each)	Acute diarrhoea	<sup>261</sup> (randomised placebo-controlled study)
<i>L. casei</i> CERELA <i>L. acidophilus</i> CERELA	Not stated Not stated	Bacterial overgrowth-related chronic diarrhoea	<sup>262</sup> (randomised, double-blind study)
<i>L. reuteri</i>	10 <sup>10–11</sup> CFU/g (1 g)	Acute diarrhoea	<sup>263</sup> (randomised, placebo-controlled study)

## Diarrhoea

Imbalance in the gut flora can cause diarrhoea, enteritis and colitis, among other diseases. VSL#3 (*St. thermophilus*, *B. breve*, *B. longum*, *B. infantis*, *L. acidophilus*, *L. plantarum*,

*L. casei* and *L. bulgaricus*) and *L. casei* DN-114 001 administration decreased the incidence and frequency of radiation therapy-induced diarrhoea.<sup>242</sup> Diarrhoea is also frequent during antibiotic therapy causing gut flora imbalance.<sup>243–244</sup>

**Table 12** Clinical studies of lactobacilli showing efficacy for treatment of periodontal disease

Bacteria	Dose	Pathology	Ref. (Design)
<i>L. salivarius</i> WB21 +	6.7×10 <sup>8</sup> CFU	Severe periodontitis treatment	<sup>274</sup> (randomised clinical study)
Xylitol	280 mg		
<i>L. reuteri</i> ATCC 55730 <i>L. reuteri</i> ATCC PTA 5289	1×10 <sup>8</sup> CFU (of each)	Gingival inflammation	<sup>275</sup> (double-blind placebo-controlled study)

**Table 13** Clinical studies of lactobacilli showing efficacy for treatment of type-2 diabetes

Bacteria	Dose	Ref. (Design)
<i>L. acidophilus</i>	2×10 <sup>9</sup> CFU	<sup>282</sup> (randomised double-blind placebo-controlled clinical study)
<i>L. casei</i>	7×10 <sup>9</sup> CFU	
<i>L. rhamnosus</i>	1.5×10 <sup>9</sup> CFU	
<i>L. bulgaricus</i>	2×10 <sup>9</sup> CFU	
<i>B. breve</i>	2×10 <sup>10</sup> CFU	
<i>B. longum</i>	7×10 <sup>9</sup> CFU	
<i>St. thermophilus</i>	1.5×10 <sup>9</sup> CFU	
+ fructo-oligosaccharide	100 mg	

*Clostridium (C.) difficile* infection, a gram positive, spore-forming anaerobe, can cause antibiotic-associated diarrhoea and colitis in humans.<sup>245 246</sup> Boonma and coworkers investigated the probiotic effect of *L. rhamnosus* L34 and *L. casei* L39, two vancomycin-resistant lactobacilli, on the suppression of IL-8 production in response to *C. difficile* infection.<sup>247</sup> While *L. casei* L39 suppressed the activation of phosphonuclear factor κ-light-chain-enhancer of activated B cells and phospho-c-Jun in HT-29 cells, *L. rhamnosus* L34 and *L. casei* L39 decreased the production of *C. difficile*-induced granulocyte-macrophage colony-stimulating factor. Moreover, *L. acidophilus* GP1B cell extract decreased transcriptional levels of luxS, tcdA, tcdB and txeR genes of *C. difficile*, thus reducing virulence in vitro.<sup>248</sup> In vivo, survival rates at 5 days for mice that received *C. difficile* and *L. acidophilus* GP1B cell extract or *L. acidophilus* GP1B were reduced up to 80%. Therefore, in vitro and in vivo investigations have showed that lactobacilli presented antibacterial effects. Clinical studies of lactobacilli showing efficacy for treatment of diarrhoea have been summarised in table 11.

### Periodontal disease

Periodontal diseases can be divided into gingivitis and periodontitis.<sup>264</sup> While the first condition is characterised by

inflammation of the gingiva,<sup>265</sup> the second is a progressive destructive disease which involves tooth supporting tissues such as the alveolar bone.<sup>266</sup> Periodontitis is mainly characterised by the presence of *Porphyromonas gingivalis*, *Treponema denticola*, *Tannerella forsythia* and *Aggregatibacter actinomycetemcomitans* which colonise the subgingival sites escaping the host defense system and eventually causing tissue damage.<sup>267</sup> Among antimicrobial and bacteriostatic agents, chlorhexidine is the gold standard for treatment of periodontitis because of its broad-spectrum antibacterial activity.<sup>268–270</sup> However, a number of side effects, such as brown teeth discolouration, salt taste perturbation, oral mucosal erosions and enhanced supragingival calculus formation, have been reported and they have limited chlorhexidine long-term use.<sup>271</sup> Evidence has shown the effectiveness of lactobacilli in reducing gingival inflammation and the number of cariogenic periodontopathogenic bacteria.<sup>272</sup> Further studies have shown that lactobacilli reduced the prevalence of moderate-to-severe gingival inflammation and improved plaque index (clinically used to measure the state of oral hygiene)<sup>273 274</sup> as well as decreased the levels of the proinflammatory cytokines TNF-α, IL-8 and IL-1β.<sup>275</sup> Saha and coworkers investigated the role of selected lactobacilli in *St. mutans* inhibition.<sup>276</sup> *L. reuteri* strains NCIMB 701359, NCIMB 701089, NCIMB 702655 and NCIMB 702656 inhibited *St. mutans* to non-detectable levels (<10 CFU/mL) suggesting their use as therapeutic agents for caries and periodontal disease. Moreover, *L. fermentum* NCIMB 5221 inhibited *St. mutans* buffering the pH (4.18) of saliva containing this pathogenic microbe and coaggregating with it also showing high levels of sucrose consumption. Altogether, these studies suggest that lactobacilli may improve oral health and reduce periodontopathogenic bacteria. Clinical studies of lactobacilli showing efficacy for treatment of periodontal diseases have been summarised in table 12.

### Diabetes

Diabetes, a chronic metabolic disease, is characterised by elevated blood glucose levels due to either insufficient insulin production by β-islet cells (type-1 diabetes) of the pancreas or

**Table 14** Clinical studies of lactobacilli showing efficacy for treatment of various pathologies

Bacteria	Dose	Pathology	Ref. (Design)
<i>L. casei</i> Shirota	Not stated	Ventilator-associated pneumonia	<sup>291</sup> (prospective, randomised, open-label controlled study)
Synbiotic 2000 ( <i>P. pentosaceus</i> 5—33:3, <i>L. mesenteroides</i> 32—77:1, <i>L. paracasei</i> 19 and <i>L. plantarum</i> 2362 + inulin, β-glucan, resistant starch and pectin)	1×10 <sup>10</sup> CFU (of each)	Severe acute pancreatitis	<sup>292</sup> (prospective, randomised, double-blind study)
Ecologic 641®: ( <i>L. acidophilus</i> , <i>L. casei</i> , <i>L. salivarius</i> , <i>Lactococcus lactis</i> , <i>B. bifidum</i> and <i>B. lactis</i> + cornstarch and maltodextrins)	Not stated 10 <sup>10</sup> CFU (total)	Severe acute pancreatitis	<sup>293</sup> (multicentre randomised, double-blind, placebo-controlled study)
Genefilus F19® ( <i>L. paracasei subsp paracasei</i> F19 + high-fibre diet)	Not stated 12×10 <sup>9</sup> CFU	Symptomatic uncomplicated diverticular disease	<sup>294</sup> (multicentre, randomised, controlled, open parallel-group study)
<i>L. GG</i>	Not stated > 5×10 <sup>10</sup> CFU	Cirrhosis	<sup>295</sup> (open study)



**Table 15** Clinical studies reporting side effects associated with *Lactobacillus* therapy

Bacteria	Effect/s	Patient(s) clinical history	Ref.
<i>L. jensenii</i>	Endocarditis	An immunocompetent 47-year-old man with mitral valve replacement treated with teicoplanin and meropenem	302
<i>L. paracasei</i>	Endocarditis	A patient (18 years) with trisomy 21 treated with chloramphenicol	303
<i>L. rhamnosus</i> GG	Bacteraemia	Eleven patients with immunosuppression, prior prolonged hospitalisation and prior surgical interventions treated with antimicrobials	317
<i>L. acidophilus</i> <i>L. bulgaricus</i>	Bloodstream infections	The maximum estimated incidence of bacteraemia during an 8-year period was 0.2%	322
<i>L. rhamnosus</i>	Bacteraemia	Sixteen nosocomial infections associated with immunosuppression (66%) and catheters (83%)	312
<i>L. rhamnosus</i> <i>L. curvatus</i> <i>L. delbrueckii</i> subsp <i>lactis</i> <i>L. paracasei</i>	Bacteraemia	Six cases of bacteraemia in hospitalised patients, five with a depressed immune status	306
<i>L. rhamnosus</i>	Hepatic abscess and bacteraemia	A 73 year-old woman with antecedent of diabetes mellitus treated with ampicillin plus gentamicin	316
<i>L. rhamnosus</i>	Catheter-related bacteraemia	A patient who underwent a single-lung transplant	308
<i>L. rhamnosus</i>	Bacteraemia	A 14-year-old girl with acute myeloid leukaemia, bacteraemia disappeared only after 13 months when the cytostatic therapy was terminated	314
<i>L. plantarum</i>	Bacteraemia	A patient (43 years) with a subacute endocarditis due to an immunovascularitis and a bloodstream infection	307
<i>L. rhamnosus</i>	Septicaemia	A 54-year-old woman with diabetes treated with amoxicillin	296
<i>L. jensenii</i>	Septicaemia	A 50-year-old woman with obstructive acute renal failure	297
<i>L. paracasei</i>	Purpura fulminans associated with liver abscess	Not stated	323
<i>L. acidophilus</i>	Liver abscess	A 27-year-old man with a 6-month history of NOD2/CARD15-positive Crohn's disease	324
<i>L. casei</i>	Pneumonia and sepsis	A patient with AIDS because of CD4 lymphocyte depletion	325
<i>L. rhamnosus</i>	Septicaemia	A patient with a graft in the inferior vena cava	298
<i>L. gasseri</i>	Septic urinary infection	A patient (66 years) developed severe urinary stasis due to a concrement in his right ureter, treated with cefotaxime and amoxicillin	326
<i>L. casei</i>	Bacteraemia	A 75-year-old woman (a heavy dairy consumer) with severe thoracic pain due to dissection of the aortic arch and ascending aorta and treated with amoxicillin	327
<i>L. rhamnosus</i> Lcr35 <i>L. rhamnosus</i> ATCC 53103	Meningitis and recurrent episodes of bacteraemia	A child (10 years ) undergoing allogeneic haematopoietic stem cell transplantation and treated unsuccessfully with clindamycin	320
<i>L. casei</i>	Bacteraemia	An immunocompetent 66-year-old man with a history of fever of unknown origin	319
<i>L. jensenii</i>	Bacteraemia and pyelonephritis	A 59-year-old woman with progressed follicular lymphoma, diabetes mellitus type-2 and arterial hypertension and kidney stone treated with antibiotics	309
<i>L. jensenii</i>	Bacteraemia and endocarditis	A 27-year-old woman with a 20-day history of fever and treated with penicillin and gentamicin	304
<i>L. rhamnosus</i>	Catheter-related bloodstream infections	A 38-year-old woman who underwent allogeneic transplantation of haematopoietic stem cells from cord blood for a large granular lymphocyte leukaemia and initially treated with chemotherapy	328
<i>L. delbrueckii</i>	Pyelonephritis and bacteraemia	A 68-year-old woman with fever, chills, nausea, and vomiting and ureteral calculus with mild left hydronephrosis treated with ampicillin	311
<i>L. rhamnosus</i>	Sepsis	A 24-year-old woman developed sepsis resulting from preoperative administration of probiotics following an aortic valve replacement	301
<i>L. rhamnosus</i> GG	Bacteraemia	A 69-year-old man with stage IIIA mantle cell lymphoma and treated with probiotic-enriched yogurt stopping	329
<i>L. rhamnosus</i> GG	Bacteraemia	An 11-month-old boy with fever and hypoxia and with a history of short bowel syndrome secondary to resection of approximately 80% of the small intestine	310
<i>L. acidophilus</i>	Sepsis	A 69-year-old man with stage IIIA mantle cell lymphoma	315
<i>L. rhamnosus</i> GG	Bacteraemia	A 36-week-gestation male infant with short gut syndrome secondary to congenital intestinal atresia and volvulus	313
<i>L. rhamnosus</i> GG	Bacteraemia	A 34-week-gestation male infant with gastroschisis	313
<i>L. rhamnosus</i>	Bacteraemia	A 43-year-old woman with ulcerative colitis	299
<i>L. paracasei</i>	Endocarditis	A 77-year-old man with a prostate cancer in remission, hiatal hernia, right hip prosthesis, mitral insufficiency, hypertension, bipolar disorder, and daily consumer of probiotics	330

impaired insulin sensitivity of insulin target organs, that is, adipose tissue, liver and muscle (type-2 diabetes or diabetes mellitus).<sup>277</sup> In this context, inflammatory immune responses play a crucial role in the progression of both types of disease.<sup>278–280</sup> As for type-2 diabetes, it is generally treated with intestinal  $\alpha$ -glucosidase inhibitors.<sup>281</sup> In this regard, *Actinoplanes* spp have been shown to naturally produce potent  $\alpha$ -glucosidase inhibitor compounds including acarbose. Panwar and coworkers

first isolated and extracted lactobacilli from human infant faecal samples and evaluated their inhibitory activity against intestinal maltase, sucrose, lactase and amylase, all enzymes involved in hydrolysis of carbohydrates.<sup>281</sup> This study showed that several strains exert powerful inhibitory effects against the aforementioned enzymes and *L. rhamnosus* reduced glucose excursions in rats during a carbohydrate challenge by inhibiting  $\beta$ -glucosidase as well as  $\alpha$ -glucosidase activities. Even if further studies are

certainly needed, administration of lactobacilli may represent a promising novel therapeutic tool for treatment of diabetes. Clinical studies of lactobacilli showing efficacy for treatment of diabetes have been summarised in [table 13](#).

### Arthritis

Osteoarthritis, a chronic joint disease characterised by progressive cartilage degeneration, subchondral bone sclerosis, synovial inflammation and osteophyte formation,<sup>283</sup> mainly affects weight-bearing joints such as knees and hips. A chronic inflammatory response occurs in synovial membranes with increased expression of proinflammatory cytokines and mononuclear cell infiltration.<sup>284</sup> Oral intake of skimmed milk fermented with *L. delbrueckii* subsp *bulgaricus* OLL1073R-1 inhibits the development of collagen-induced arthritis in mice. Moreover, a reduced secretion of IFN- $\gamma$  was also observed in these animals.<sup>285</sup> Moreover, *L. casei* suppresses experimental rheumatoid arthritis by downregulating Th1-type inflammatory responses<sup>286</sup> and its coadministration with type-II collagen and glucosamine decreased the expression of various proinflammatory cytokines and matrix metalloproteinases, upregulating anti-inflammatory cytokines.<sup>287</sup> The immunomodulating activity of lactobacilli in rheumatoid arthritis was also confirmed by a trial on 45 adult men and women affected by this pathology.<sup>288</sup> *Bacillus coagulans* GBI-30, 6086, administered for 60 days in addition to standard antiarthritic medications, resulted in an improvement in the Patient Pain Assessment score and statistically significant improvement in Pain Scale with respect to placebo.

### Other pathologies

Lactobacilli have found application for treatment of several other pathologies. For instance, *L. plantarum* strain K21 that inhibits lipid accumulation in 3T3-L1 preadipocytes, alleviated body weight gain and epididymal fat mass accumulation, reduced plasma leptin levels, decreased cholesterol and triglyceride levels as well as mitigated liver damage in a mouse model of diet-induced obesity.<sup>289</sup> Antilipidemic effects of lactobacilli were also evaluated along with memory-enhancing activity in aged Fischer 344 rats.<sup>290</sup> A probiotic mixture of *L. plantarum* KY1032 and *L. curvatus* HY7601 was provided once a day for 8 weeks. A significant inhibition of age-dependent increase in blood triglycerides and a reduction in high-density lipoprotein cholesterol was observed. Moreover, the mixture restored age-reduced spontaneous alternation in the Y-maze task and age-suppressed doublecortin and brain derived neurotrophic factor expression. In addition, suppression of p16, p53 and cyclooxygenase-2 expression, phosphorylation of protein kinase B and mammalian target of rapamycin and activation of nuclear factor  $\kappa$ -light-chain-enhancer of activated B cells were observed, thus suggesting a therapeutic role of such mixture in ameliorating age-dependent memory deficit and lipidemia in aged subjects. Clinical studies of lactobacilli showing efficacy for treatment of various pathologies have been summarised in [table 14](#).

### SIDE EFFECTS OF LACTOBACILLI

The widespread clinical use of lactobacilli, even for pathologies that are challenging to treat, has highlighted potential translocations or mutations and untoward effects such as sepsis,<sup>296–301</sup> endocarditis,<sup>302–305</sup> bacteraemia<sup>299 306–319</sup> and even death.<sup>320</sup> Evidence regarding lactobacilli side effect profile has been summarised in [table 15](#).

### CONCLUSIONS

The mammalian gut microbiome interacts with several physiological systems within the host contributing to multiple biological processes. In vitro and in vivo investigations have shown that prolonged probiotic administration induces qualitative and quantitative modifications in complex, well-settled microbial ecosystems through bacteriocin substrate competition and possibly other mechanisms that still need to be acknowledged. Probiotics can modulate the GI tract microbial ecology exerting immunomodulatory effects that are therapeutic at least for treatment of specific pathologies.<sup>331</sup> Our review takes into account the available clinical and experimental evidence on the use of lactobacilli in order to give an overview of their suitability to be enclosed in well defined updated therapeutic protocols for specific pathologies. A limited number of studies have already tested the hypothesis that lactobacilli could be combined with bifidobacteria or other nutrients, such as fibres, in order to enhance the bioavailability, mucosal adhesion and therapeutic effectiveness of lactobacilli. Further studies are certainly warranted to determine the most effective combinations for treatment of individual pathologies. The claim that pools of lactobacilli could better survive within the gut lumen and even in the colon, and stably integrate within the pre-existing microbiome, has never been proved in terms of dose-effect and risk of sepsis and bacteraemia. We do not have enough information about the long-term genetic stability (with some exceptions such as *L. paracasei* subsp *paracasei* F19<sup>332 333</sup>), the antibiotic susceptibility and translocation rate of *L.* strains.<sup>334–336</sup> Therefore, further investigations are required to fill in this gap. We would also like to point out the increasing interest in lactobacilli used for industrial food fermentation which has reached a high degree of sophistication that could be useful also for medical applications.<sup>337</sup> For example, various novel biological modifications have been introduced such as the lysostaphin-expressing gene to prevent growth of toxic shock syndrome toxin 1 producing strains of *S. aureus*.<sup>338</sup>

However, since data concerning the safety and genetic stability of lactobacilli is still limited, toxicological studies evaluating the effects of their genetic modification on the homeostasis of the host organism are still required. Ongoing research on the human microbiome composition will likely yield new species of the genus *L.* that might also have therapeutic applications for specific pathologies.

### Take home messages

- Experimental and clinical evidence supports effectiveness of lactobacilli for treatment of several pathological conditions.
- Long-term consumption of lactobacilli induces qualitative and quantitative modifications in the human gastrointestinal microbial ecosystem.
- Pharmacological profile of lactobacilli needs to be further characterised in order to avoid translocation-related risks.

**Correction notice** Since this paper was published online the author has changed the formatting of tables 2–15, corrected the units in these tables and added italics to gene names throughout the paper.

**Handling editor** Slade Jensen

**Acknowledgements** JCMM acknowledges CONAcYT for membership.

**Contributors** All the authors contributed equally to this work.

**Competing interests** None declared

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## REFERENCES

- Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. *Nat Rev Neurosci* 2012;13:701–12.
- Clarke G, Stilling RM, Kennedy PJ, et al. Mini-review: gut microbiota: the neglected endocrine organ. *Mol Endocrinol* 2014;28:1221–38.
- El Aidy S, Dinan TG, Cryan JF. Gut microbiota: the conductor in the orchestra of immune-neuroendocrine communication. *Clin Ther* 2015;37:954–67.
- Adlerberth I, Wold AE. Establishment of the gut microbiota in Western infants. *Acta Paediatr* 2009;98:229–38.
- Chassard C, de Wouters T, Lacroix C. Probiotics tailored to the infant: a window of opportunity. *Curr Opin Biotechnol* 2014;26:141–7.
- Samot J, Lebreton J, Badet C. Adherence capacities of oral lactobacilli for potential probiotic purposes. *Anaerobe* 2011;17:69–72.
- Sengupta R, Altermann E, Anderson RC, et al. The role of cell surface architecture of lactobacilli in host-microbe interactions in the gastrointestinal tract. *Mediators Inflamm* 2013;2013:237921.
- Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: a review. *Altern Med Rev* 2004;9:180–97.
- Ouweland AC, Salminen S, Isolauri E. Probiotics: an overview of beneficial effects. *Antonie Van Leeuwenhoek* 2013;82:279–89.
- Michail S. The mechanism of action of probiotics. *Pract Gastroenterol* 2005;2:29–47.
- Rescigno M. The intestinal epithelial barrier in the control of homeostasis and immunity. *Trends Immunol* 2011;32:256–64.
- Polak-Berecka M, Wasko A, Paduch R, et al. The effect of cell surface components on adhesion ability of *Lactobacillus rhamnosus*. *Antonie Van Leeuwenhoek* 2014;106:751–62.
- Yadav AK, Tyagi A, Kumar A, et al. Adhesion of indigenous *Lactobacillus plantarum* to gut extracellular matrix and its physicochemical characterization. *Arch Microbiol* 2015;197:155–64.
- Fujiwara S, Seto Y, Kimura A, et al. Establishment of orally-administered *Lactobacillus gasseri* SBT2055SR in the gastrointestinal tract of humans and its influence on intestinal microflora and metabolism. *J Appl Microbiol* 2001;90:343–52.
- Hutt P, Koll P, Stsepetova J, et al. Safety and persistence of orally administered human *Lactobacillus* sp. strains in healthy adults. *Benef Microbes* 2011;2:79–90.
- Rosenfeldt V, Pærregaard A, Larsen CN, et al. Faecal recovery, mucosal adhesion, gastrointestinal effects and tolerance of mixed cultures of potential probiotic lactobacilli. *Microbiol Ecol Health Dis* 2011;15:2–9.
- Jacobsen CN, Rosenfeldt Nielsen V, Hayford AE, et al. Screening of probiotic activities of forty-seven strains of *Lactobacillus* spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. *Appl Environ Microbiol* 1999;65:4949–56.
- Hughes R, Rowland IR. Metabolic activities of the gut microflora in relation to cancer. *Microbiol Ecol Health Dis* 2000;12:179–85.
- Liong MT. Roles of probiotics and prebiotics in colon cancer prevention: postulated mechanisms and in-vivo evidence. *Int J Mol Sci* 2008;9:854–63.
- Heaton KW. The large intestine in nutrition and disease. *J R Soc Med* 1997;90:410.
- Goldin BR, Gorbach SL. The effect of milk and lactobacillus feeding on human intestinal bacterial enzyme activity. *Am J Clin Nutr* 1984;39:756–61.
- Tannock GW, Munro K, Harmsen HJM, et al. Analysis of the Fecal Microflora of Human Subjects Consuming a Probiotic Product Containing *Lactobacillus rhamnosus* DR20. *Appl Environ Microbiol* 2000;66:2578–88.
- Marteau P, Pochart P, Flourie B, et al. Effect of chronic ingestion of a fermented dairy product containing *Lactobacillus acidophilus* and *Bifidobacterium bifidum* on metabolic activities of the colonic flora in humans. *Am J Clin Nutr* 1990;52:685–8.
- Goldin BR, Swenson L, Dwyer J, et al. Effect of Diet and *Lactobacillus acidophilus* Supplements on Human Fecal Bacterial Enzymes. *J Natl Cancer Inst* 1980;64:255–61.
- Lidbeck A, Nord CE, Gustafsson JA, et al. Lactobacilli, anticarcinogenic activities and human intestinal microflora. *Eur J Cancer Prev* 1992;1:341–53.
- Bertkova I, Hijoja E, Chmelařova A, et al. The effect of probiotic microorganisms and bioactive compounds on chemically induced carcinogenesis in rats. *Neoplasma* 2010;57:422–8.
- Van Tassel RL, Kingston DG, Wilkins TD. Metabolism of dietary genotoxins by the human colonic microflora; the fecapentaenes and heterocyclic amines. *Mutat Res* 1990;238:209–21.
- Kumar M, Kumar A, Nagpal R, et al. Cancer-preventing attributes of probiotics: an update. *Int J Food Sci Nutr* 2010;61:473–96.
- Orrhage K, Sillerström E, Gustafsson JA, et al. Binding of mutagenic heterocyclic amines by intestinal and lactic acid bacteria. *Mutat Res* 1994;311:239–48.
- Sreekumar O, Hosono A. The antimutagenic properties of a polysaccharide produced by *Bifidobacterium longum* and its cultured milk against some heterocyclic amines. *Can J Microbiol* 1998;44:1029–36.
- Sreekumar O, Hosono A. The heterocyclic amine binding receptors of *Lactobacillus gasseri* cells. *Mutat Res* 1998;421:65–72.
- Zhang XB, Ohta Y. Antimutagenicity of cell fractions of microorganisms on potent mutagenic pyrolysates. *Mutat Res* 1993;298:247–53.
- Sreekumar O, Hosono A. Antimutagenicity and the influence of physical factors in binding *Lactobacillus gasseri* and *Bifidobacterium longum* cells to amino acid pyrolysates. *J Dairy Sci* 1998;81:1508–16.
- Rhee CH, Park HD. Three glycoproteins with antimutagenic activity identified in *Lactobacillus plantarum* KLAB21. *Appl Environ Microbiol* 2001;67:3445–9.
- Challa A, Rao DR, Chawan CB, et al. *Bifidobacterium longum* and lactulose suppress azoxymethane-induced colonic aberrant crypt foci in rats. *Carcinogenesis* 1997;18:517–21.
- Manning TS, Gibson GR. Microbial-gut interactions in health and disease. Prebiotics. *Best Pract Res Clin Gastroenterol* 2004;18:287–98.
- Huycke MM, Gaskins HR. Commensal bacteria, redox stress, and colorectal cancer: mechanisms and models. *Exp Biol Med (Maywood)* 2004;229:586–97.
- Sobhani I, Tap J, Roudot-Thoraval F, et al. Microbial dysbiosis in colorectal cancer (CRC) patients. *PLoS ONE* 2011;6:e16393.
- Rafter J, Bennett M, Caderni G, et al. Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. *Am J Clin Nutr* 2007;85:488–96.
- O'Mahony L, Feeney M, O'Halloran S, et al. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. *Aliment Pharmacol Ther* 2001;15:1219–25.
- Sekine K, Toida T, Saito M, et al. A new morphologically characterized cell wall preparation (whole peptidoglycan) from *Bifidobacterium infantis* with a higher efficacy on the regression of an established tumor in mice. *Cancer Res* 1985;45:1300–7.
- Yokokura T, Kato I, Matsuzaki T, et al. [Antitumor activity of *Lactobacillus casei* YIT 9018 (LC 9018)—effect of administration route]. *Gan To Kagaku Ryoho* 1984;11:2427–33.
- Matsuzaki T, Yokokura T, Azuma I. Anti-tumour activity of *Lactobacillus casei* on Lewis lung carcinoma and line-10 hepatoma in syngeneic mice and guinea pigs. *Cancer Immunol Immunother* 1985;20:18–22.
- Matsuzaki T, Yokokura T, Mutai M. Antitumor effect of intrapleural administration of *Lactobacillus casei* in mice. *Cancer Immunol Immunother* 1988;26:209–14.
- Aso Y, Akaza H, Kotake T, et al. Preventive effect of a *Lactobacillus casei* preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. *Eur Urol* 1995;27:104–9.
- Aso Y, Akazan H. Prophylactic effect of a *Lactobacillus casei* preparation on the recurrence of superficial bladder cancer. BLP Study Group. *Urol Int* 1992;49:125–9.
- Matsuzaki T. Immunomodulation by treatment with *Lactobacillus casei* strain Shirota. *Int J Food Microbiol* 1998;41:133–40.
- Takagi A, Matsuzaki T, Sato M, et al. Inhibitory effect of oral administration of *Lactobacillus casei* on 3-methylcholanthrene-induced carcinogenesis in mice. *Med Microbiol Immunol* 1999;188:111–16.
- Takagi A, Matsuzaki T, Sato M, et al. Enhancement of natural killer cytotoxicity delayed murine carcinogenesis by a probiotic microorganism. *Carcinogenesis* 2001;22:599–605.
- Foligne B, Zoumpopoulou G, Dewulf J, et al. A key role of dendritic cells in probiotic functionality. *PLoS ONE* 2007;2:e313.
- Yasui H, Shida K, Matsuzaki T, et al. Immunomodulatory function of lactic acid bacteria. *Antonie Van Leeuwenhoek* 1999;76:383–9.
- Lee JW, Shin JG, Kim EH, et al. Immunomodulatory and antitumor effects in vivo by the cytoplasmic fraction of *Lactobacillus casei* and *Bifidobacterium longum*. *J Vet Sci* 2004;5:41–8.
- Takagi A, Ikemura H, Matsuzaki T, et al. Relationship between the in vitro response of dendritic cells to *Lactobacillus* and prevention of tumorigenesis in the mouse. *J Gastroenterol* 2008;43:661–9.
- Matsumoto S, Hara T, Nagaoka M, et al. A component of polysaccharide peptidoglycan complex on *Lactobacillus* induced an improvement of murine model of inflammatory bowel disease and colitis-associated cancer. *Immunology* 2009;128(1 Suppl):e170–80.
- Iyer C, Kusters A, Sethi G, et al. Probiotic *Lactobacillus reuteri* promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling. *Cell Microbiol* 2008;10:1442–52.
- Otte JM, Mahjirian-Namari R, Brand S, et al. Probiotics regulate the expression of COX-2 in intestinal epithelial cells. *Nutr Cancer* 2009;61:103–13.
- Le Leu RK, Brown IL, Hu Y, et al. A synbiotic combination of resistant starch and *Bifidobacterium lactis* facilitates apoptotic deletion of carcinogen-damaged cells in rat colon. *J Nutr* 2005;135:996–1001.



- 58 Sadeghi-Aliabadi H, Mohammadi F, Fazeli H, *et al.* Effects of *Lactobacillus plantarum* A7 with probiotic potential on colon cancer and normal cells proliferation in comparison with a commercial strain. *Iran J Basic Med Sci* 2014;17:815–19.
- 59 Baricault L, Denariac G, Houri JJ, *et al.* Use of HT-29, a cultured human colon cancer cell line, to study the effect of fermented milks on colon cancer cell growth and differentiation. *Carcinogenesis* 1995;16:245–52.
- 60 Grimoud J, Durand H, de Souza S, *et al.* In vitro screening of probiotics and synbiotics according to anti-inflammatory and anti-proliferative effects. *Int J Food Microbiol* 2010;144:42–50.
- 61 Singh J, Rivenson A, Tomita M, *et al.* *Bifidobacterium longum*, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. *Carcinogenesis* 1997;18: 833–41.
- 62 Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. *Physiol Rev* 2001;81:1031–64.
- 63 Whitehead RH, Young GP, Bhathal PS. Effects of short chain fatty acids on a new human colon carcinoma cell line (LIM1215). *Gut* 1986;27:1457–63.
- 64 Liew C, Schut HA, Chin SF, *et al.* Protection of conjugated linoleic acids against 2-amino-3-methylimidazo[4,5-f]quinoline-induced colon carcinogenesis in the F344 rat: a study of inhibitory mechanisms. *Carcinogenesis* 1995;16:3037–43.
- 65 Clausen MR, Bonnen H, Mortensen PB. Colonic fermentation of dietary fibre to short chain fatty acids in patients with adenomatous polyps and colonic cancer. *Gut* 1991;32:923–8.
- 66 Walker AR, Walker BF, Walker AJ. Faecal pH, dietary fibre intake, and proneness to colon cancer in four South African populations. *Br J Cancer* 1986;53:489–95.
- 67 Ohkawara S, Furuya H, Nagashima K, *et al.* Oral administration of butyrylvibrio fibrisolvens, a butyrate-producing bacterium, decreases the formation of aberrant crypt foci in the colon and rectum of mice. *J Nutr* 2005;135:2878–83.
- 68 Lan A, Lagadic-Gossman D, Lemaire C, *et al.* Acidic extracellular pH shifts colorectal cancer cell death from apoptosis to necrosis upon exposure to propionate and acetate, major end-products of the human probiotic propionibacteria. *Apoptosis* 2007;12:573–91.
- 69 Jan G, Belzacq AS, Haouzi D, *et al.* Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. *Cell Death Differ* 2002;9:179–88.
- 70 Borowicki A, Michelmann A, Stein K, *et al.* Fermented wheat aleurone enriched with probiotic strains LGG and Bb12 modulates markers of tumor progression in human colon cells. *Nutr Cancer* 2011;63:151–60.
- 71 Evans NP, Misyak SA, Schmelz EM, *et al.* Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma. *J Nutr* 2010;140:515–21.
- 72 Kim KH, Park HS. Dietary supplementation of conjugated linoleic acid reduces colon tumor incidence in DMH-treated rats by increasing apoptosis with modulation of biomarkers. *Nutrition* 2003;19:772–7.
- 73 Rao CV, Sanders ME, Indranie C, *et al.* Prevention of colonic preneoplastic lesions by the probiotic *Lactobacillus acidophilus* NCFMTM in F344 rats. *Int J Oncol* 1999;14:939–44.
- 74 Yasutake N, Matsuzaki T, Kimura K, *et al.* The role of tumor necrosis factor (TNF)-alpha in the antitumor effect of intrapleural injection of *Lactobacillus casei* strain Shirota in mice. *Med Microbiol Immunol* 1999;188:9–14.
- 75 McIntosh GH, Royle PJ, Playne MJ. A probiotic strain of *L. acidophilus* reduces DMH-induced large intestinal tumors in male Sprague-Dawley rats. *Nutr Cancer* 1999;35:153–9.
- 76 Horinaka M, Yoshida T, Kishi A, *et al.* *Lactobacillus* strains induce TRAIL production and facilitate natural killer activity against cancer cells. *FEBS Lett* 2010;584:577–82.
- 77 Baldwin C, Millette M, Oth D, *et al.* Probiotic *Lactobacillus acidophilus* and *L. casei* mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. *Nutr Cancer* 2010;62:371–8.
- 78 El-Nezami HS, Polychronaki NN, Ma J, *et al.* Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China. *Am J Clin Nutr* 2006;83:1199–203.
- 79 Zhang JW, Du P, Gao J, *et al.* Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. *Am J Med Sci* 2012;343:199–205.
- 80 Ohgashi S, Hoshino Y, Ohde S, *et al.* Functional outcome, quality of life, and efficacy of probiotics in postoperative patients with colorectal cancer. *Surg Today* 2011;41:1200–6.
- 81 Vasama M, Kumar H, Salminen S, *et al.* Removal of paralytic shellfish toxins by probiotic lactic acid bacteria. *Toxins (Basel)* 2014;6:2127–36.
- 82 Nowak A, Kuberski S, Libudzisz Z. Probiotic lactic acid bacteria detoxify N-nitrosodimethylamine. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess* 2014;31:1678–87.
- 83 Mechoud MA, Juarez GE, de Valdez GF, *et al.* *Lactobacillus reuteri* CRL 1098 and *Lactobacillus acidophilus* CRL 1014 differently reduce in vitro immunotoxic effect induced by Ochratoxin A. *Food Chem Toxicol* 2012;50:4310–15.
- 84 Petzinger E, Ziegler K. Ochratoxin A from a toxicological perspective. *J Vet Pharmacol Ther* 2000;23:91–8.
- 85 Skopinska E, Lachowicz D, Wultanska D, *et al.* [Assessment of antagonistic activity in vitro *Lactobacillus* spp. strains against *Clostridium difficile* strains isolated from gastrointestinal tract of patients hospitalized in three hospitals in region Mazovia]. *Med Dosw Mikrobiol* 2012;64:109–14.
- 86 Li J, Wang W, Xu SX, *et al.* *Lactobacillus reuteri*-produced cyclic dipeptides quench agr-mediated expression of toxic shock syndrome toxin-1 in staphylococci. *Proc Natl Acad Sci USA* 2011;108:3360–5.
- 87 Fei YT, Liu DM, Luo TH, *et al.* Molecular characterization of *Lactobacillus plantarum* DMDL 9010, a strain with efficient nitrite degradation capacity. *PLoS ONE* 2014;9:e113792.
- 88 Satarug S, Garrett SH, Sens MA, *et al.* Cadmium, environmental exposure, and health outcomes. *Environ Health Perspect* 2010;118:182–90.
- 89 Gerbino E, Carasi P, Tymczynyn EE, *et al.* Removal of cadmium by *Lactobacillus kefir* as a protective tool against toxicity. *J Dairy Res* 2014;81:280–7.
- 90 Witkin SS. The vaginal microbiome, vaginal anti-microbial defence mechanisms and the clinical challenge of reducing infection-related preterm birth. *BJOG* 2015;122:213–18.
- 91 Liu H, Gao Y, Yu LR, *et al.* Inhibition of *Staphylococcus aureus* by lysostaphin-expressing *Lactobacillus plantarum* WCFS1 in a modified genital tract secretion medium. *Appl Environ Microbiol* 2011;77:8500–8.
- 92 Kaewsrirach J, Peeyanjanjarassri K, Kongprasertkit J. Selection and identification of anaerobic lactobacilli producing inhibitory compounds against vaginal pathogens. *FEMS Immunol Med Microbiol* 2006;48:75–83.
- 93 Graver MA, Wade JJ. Growth and acidification by vaginal lactobacilli in anaerobic liquid medium over the pH range 5.5–8.0. *J Bacteriol Parasitol* 2010;1:1–3.
- 94 Atassi F, Brassart D, Grob P, *et al.* *Lactobacillus* strains isolated from the vaginal microbiota of healthy women inhibit *Prevotella bivia* and *Gardnerella vaginalis* in coculture and cell culture. *FEMS Immunol Med Microbiol* 2006;48:424–32.
- 95 Pashaian MM, Oganessian GG. [Isolation and characterization of vaginal lactobacilli producing hydrogen peroxide]. *Zh Mikrobiol Epidemiol Immunobiol* 2011;90–3.
- 96 Lazarenko L, Babenko L, Sichel LS, *et al.* Antagonistic action of lactobacilli and bifidobacteria in relation to staphylococcus aureus and their influence on the immune response in cases of intravaginal staphylococcosis in mice. *Probiotics Antimicrob Proteins* 2012;4:78–89.
- 97 De Seta F, Parazzini F, De Leo R, *et al.* *Lactobacillus plantarum* P17630 for preventing Candida vaginitis recurrence: a retrospective comparative study. *Eur J Obstet Gynecol Reprod Biol* 2014;182:136–9.
- 98 Sobel JD. Recurrent vulvovaginal candidiasis: A prospective study of the efficacy of maintenance ketoconazole therapy. *N Engl J Med* 1986;315:1455–8.
- 99 Winn HN. Group B streptococcus infection in pregnancy. *Clin Perinatol* 2007;34:387–92.
- 100 De Gregorio PR, Juarez Tomas MS, Leccese Terraf MC, *et al.* Preventive effect of *Lactobacillus reuteri* CRL1324 on Group B Streptococcus vaginal colonization in an experimental mouse model. *J Appl Microbiol* 2015;118:1034–47.
- 101 Baker CJ, Edwards MS. Group B streptococcal infections. In: Remington JS, Klein JO, eds. *Infectious diseases of the fetus and newborn infant*. Philadelphia: W.B. Saunders Co., 2001:1091–156.
- 102 Reid G, Charbonneau D, Erb J, *et al.* Oral use of *Lactobacillus rhamnosus* GR-1 and *L. fermentum* RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. *FEMS Immunol Med Microbiol* 2003;35:131–4.
- 103 Di Piero F, Di Paola G, Risso P. Role of a medical device for intra-vaginal use in improving the quality of the colposcopic examination and the anatomical/pathological reading of the cytological test and biopsy. *Acta Biomed* 2014;85:121–6.
- 104 Ehrstrom S, Daroczy K, Rylander E, *et al.* Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis. *Microbes Infect* 2010;12:691–9.
- 105 Murina F, Graziottin A, Vicariotto F, *et al.* Can *Lactobacillus fermentum* LF10 and *Lactobacillus acidophilus* LA02 in a slow-release vaginal product be useful for prevention of recurrent vulvovaginal candidiasis?: a clinical study. *J Clin Gastroenterol* 2014;48(Suppl 1):S102–5.
- 106 Vicariotto F, Mogna L, Del Piano M. Effectiveness of the two microorganisms *Lactobacillus fermentum* LF15 and *Lactobacillus plantarum* LP01, formulated in slow-release vaginal tablets, in women affected by bacterial vaginosis: a pilot study. *J Clin Gastroenterol* 2014;48(Suppl 1):S106–12.
- 107 Mastromarino P, Macchia S, Meggiorini L, *et al.* Effectiveness of *Lactobacillus*-containing vaginal tablets in the treatment of symptomatic bacterial vaginosis. *Clin Microbiol Infect* 2009;15:67–74.
- 108 Petricevic L, Unger FM, Viernstein H, *et al.* Randomized, double-blind, placebo-controlled study of oral lactobacilli to improve the vaginal flora of postmenopausal women. *Eur J Obstet Gynecol Reprod Biol* 2008;141:54–7.
- 109 Larsson PG, Stray-Pedersen B, Rytting KR, *et al.* Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the



- recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. *BMC Womens Health* 2008;8:3.
- 110 De Smet I, De Boever P, Verstraete W. Cholesterol lowering in pigs through enhanced bacterial bile salt hydrolase activity. *Br J Nutr* 1998;79:185–94.
  - 111 Kumar R, Grover S, Batish VK. Hypocholesterolaemic effect of dietary inclusion of two putative probiotic bile salt hydrolase-producing *Lactobacillus plantarum* strains in Sprague-Dawley rats. *Br J Nutr* 2011;105:561–73.
  - 112 Liong MT, Shah NP. Production of organic acids from fermentation of mannitol, fructooligosaccharide and inulin by a cholesterol removing *Lactobacillus acidophilus* strain. *J Appl Microbiol* 2005;99:783–93.
  - 113 Anandharaj M, Sivasankari B. Isolation of potential probiotic *Lactobacillus oris* HMI68 from mother's milk with cholesterol-reducing property. *J Biosci Bioeng* 2014;118:153–9.
  - 114 Tomaro-Duchesneau C, Jones ML, Shah D, et al. Cholesterol assimilation by *Lactobacillus* probiotic bacteria: an in vitro investigation. *BioMed Res Int* 2014;2014:380316.
  - 115 Tomaro-Duchesneau C, Saha S, Malhotra M, et al. Probiotic ferulic acid esterase active *Lactobacillus fermentum* NCIMB 5221 APA microcapsules for oral delivery: preparation and in vitro characterization. *Pharmaceuticals (Basel)* 2012;5: 236–48.
  - 116 Kim HK, Jeong TS, Lee MK, et al. Lipid-lowering efficacy of hesperetin metabolites in high-cholesterol fed rats. *Clin Chim Acta Clinica chimica* 2003;327:129–37.
  - 117 Anandharaj M, Sivasankari B, Santhanakuruppu R, et al. Determining the probiotic potential of cholesterol-reducing *Lactobacillus* and *Weissella* strains isolated from gherkins (fermented cucumber) and south Indian fermented koozh. *Res Microbiol* 2015;166:428–39.
  - 118 Fuentes MC, Lajo T, Carrion JM, et al. Cholesterol-lowering efficacy of *Lactobacillus plantarum* CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. *Br J Nutr* 2013;109:1866–72.
  - 119 Anderson JW, Gilliland SE. Effect of Fermented Milk (Yogurt) Containing *Lactobacillus Acidophilus* L1 on Serum Cholesterol in Hypercholesterolemic Humans. *J Am Coll Nutr* 1999;18:43–50.
  - 120 Jones ML, Martoni CJ, Parent M, et al. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active *Lactobacillus reuteri* NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. *Br J Nutr* 2012;107:1505–13.
  - 121 Ataie-Jafari A, Larijani B, Alavi Majd H, et al. Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects. *Ann Nutr Metab* 2009;54:22–7.
  - 122 Uskova MA, Kravchenko LV. [Antioxidant properties of lactic acid bacteria—probiotic and yogurt strains]. *Vopr Pitan* 2009;78:18–23.
  - 123 Sun J, Hu XL, Le GW, et al. *Lactobacilli* prevent hydroxy radical production and inhibit *Escherichia coli* and *Enterococcus* growth in system mimicking colon fermentation. *Lett Appl Microbiol* 2010;50:264–9.
  - 124 Li S, Zhao Y, Zhang L, et al. Antioxidant activity of *Lactobacillus plantarum* strains isolated from traditional Chinese fermented foods. *Food Chem* 2012;135:1914–19.
  - 125 Amaretti A, di Nunzio M, Pompei A, et al. Antioxidant properties of potentially probiotic bacteria: in vitro and in vivo activities. *Appl Microbiol Biotechnol* 2013;97:809–17.
  - 126 de Waard R, Garssen J, Bokken GC, et al. Antagonistic activity of *Lactobacillus casei* strain shirota against gastrointestinal *Listeria monocytogenes* infection in rats. *Int J Food Microbiol* 2002;73:93–100.
  - 127 Bredholt S, Nesbakken T, Holck A. Protective cultures inhibit growth of *Listeria monocytogenes* and *Escherichia coli* O157:H7 in cooked, sliced, vacuum- and gas-packaged meat. *Int J Food Microbiol* 1999;53:43–52.
  - 128 Forestier C, De Champs C, Vatoux C, et al. Probiotic activities of *Lactobacillus casei rhamnosus*: in vitro adherence to intestinal cells and antimicrobial properties. *Res Microbiol* 2001;152:167–73.
  - 129 Michail S, Abernathy F. *Lactobacillus plantarum* reduces the in vitro secretory response of intestinal epithelial cells to enteropathogenic *Escherichia coli* infection. *J Pediatr Gastroenterol Nutr* 2002;35:350–5.
  - 130 Dicks LM, ten Doeschate K. *Enterococcus mundtii* ST45A and *Lactobacillus plantarum* 423 alleviated symptoms of *Salmonella* infection, as determined in Wistar rats challenged with *Salmonella enterica* serovar Typhimurium. *Curr Microbiol* 2010;61:184–9.
  - 131 Shukla G, Devi P, Sehgal R. Effect of *Lactobacillus casei* as a probiotic on modulation of giardiasis. *Dig Dis Sci* 2008;53:2671–9.
  - 132 Coconnier MH, Lievin V, Lorrot M, et al. Antagonistic activity of *Lactobacillus acidophilus* LB against intracellular *Salmonella enterica* serovar Typhimurium infecting human enterocyte-like Caco-2/TC-7 cells. *Appl Environ Microbiol* 2000;66:1152–7.
  - 133 Shokryazdan P, Sieo CC, Kalavathy R, et al. Probiotic potential of *Lactobacillus* strains with antimicrobial activity against some human pathogenic strains. *BioMed Res Int* 2014;2014:927268.
  - 134 Meira SM, Helfer VE, Velho RV, et al. Probiotic potential of *Lactobacillus* spp. isolated from Brazilian regional ovine cheese. *J Dairy Res* 2012; 79:119–27.
  - 135 Kang MS, Oh JS, Lee HC, et al. Inhibitory effect of *Lactobacillus reuteri* on periodontopathic and cariogenic. *J Microbiol* 2011;49:193–9.
  - 136 Guo J, Mauch A, Galle S, et al. Inhibition of growth of *Trichophyton tonsurans* by *Lactobacillus reuteri*. *J Appl Microbiol* 2011;111:474–83.
  - 137 Zhang Y, Zhang L, Du M, et al. Antimicrobial activity against *Shigella sonnei* and probiotic properties of wild *Lactobacilli* from fermented food. *Microbiol Res* 2011;167:27–31.
  - 138 Asahara T, Shimizu K, Takada T, et al. Protective effect of *Lactobacillus casei* strain Shirota against lethal infection with multi-drug resistant *Salmonella enterica* serovar Typhimurium DT104 in mice. *J Appl Microbiol* 2011;110:163–73.
  - 139 Nielsen DS, Cho GS, Hanak A, et al. The effect of bacteriocin-producing *Lactobacillus plantarum* strains on the intracellular pH of sessile and planktonic *Listeria monocytogenes* single cells. *Int J Food Microbiol* 2010;141(Suppl 1): S53–9.
  - 140 Bernardeau M, Gueguen M, Smith DG, et al. In vitro antagonistic activities of *Lactobacillus* spp. against *Brachyspira hyodysenteriae* and *Brachyspira pilosicoli*. *Vet Microbiol* 2009;138:184–90.
  - 141 Lavermicocca P, Valerio F, Lonigro SL, et al. Antagonistic activity of potential probiotic *Lactobacilli* against the ureolytic pathogen *Yersinia enterocolitica*. *Curr Microbiol* 2008;56:175–81.
  - 142 Coman MM, Verdenelli MC, Cecchini C, et al. In vitro evaluation of antimicrobial activity of *Lactobacillus rhamnosus* IMC 501(R), *Lactobacillus paracasei* IMC 502(R) and *SYNBIO(R)* against pathogens. *J Appl Microbiol* 2014;117: 518–27.
  - 143 Bolla PA, Carasi P, Serradell Mde L, et al. Kefir-isolated *Lactococcus lactis* subsp. *lactis* inhibits the cytotoxic effect of *Clostridium difficile* in vitro. *J Dairy Res* 2013;80:96–102.
  - 144 Zhang D, Li R, Li J. *Lactobacillus reuteri* ATCC 55730 and L22 display probiotic potential in vitro and protect against *Salmonella*-induced pullorum disease in a chick model of infection. *Res Vet Sci* 2012;93:366–73.
  - 145 Martin R, Olivares M, Marin ML, et al. Characterization of a reuterin-producing *Lactobacillus coryniformis* strain isolated from a goat's milk cheese. *Int J Food Microbiol* 2005;104:267–77.
  - 146 Aween MM, Hassan Z, Muhialdin BJ, et al. Antibacterial activity of *Lactobacillus acidophilus* strains isolated from honey marketed in Malaysia against selected multiple antibiotic resistant (MAR) Gram-positive bacteria. *J Food Sci* 2012;77: M364–71.
  - 147 Cadieux PA, Burton J, Devillard E, et al. *Lactobacillus* by-products inhibit the growth and virulence of uropathogenic *Escherichia coli*. *J Physiol Pharmacol* 2009;60(Suppl 6):13–8.
  - 148 Teanpaisan R, Piwat S, Dahlen G. Inhibitory effect of oral *Lactobacillus* against oral pathogens. *Lett Appl Microbiol* 2011;53:452–9.
  - 149 Mapple LJ, Tchorezewska MA, Cooley WA, et al. *Lactobacilli* antagonize the growth, motility, and adherence of *Brachyspira pilosicoli*: a potential intervention against avian intestinal spirochetosis. *Appl Environ Microbiol* 2011;77:5402–11.
  - 150 Jebur M. Therapeutic efficacy of *Lactobacillus acidophilus* against bacterial isolates from burn wounds. *N Am J Med Sci* 2010;2:586–91.
  - 151 Asahara T, Nomoto K, Watanuki M, et al. Antimicrobial activity of intraurethrally administered probiotic *Lactobacillus casei* in a murine model of *Escherichia coli* urinary tract infection. *Antimicrob Agents Chemother* 2001;45:1751–60.
  - 152 Pridmore RD, Pittet AC, Praplan F, et al. Hydrogen peroxide production by *Lactobacillus johnsonii* NCC 533 and its role in anti-*Salmonella* activity. *FEMS Microbiol Lett* 2008;283:210–15.
  - 153 Castillo NA, de Moreno de LeBlanc A, C MG, Perdigon G. Comparative study of the protective capacity against *Salmonella* infection between probiotic and nonprobiotic *Lactobacilli*. *J Appl Microbiol* 2013;114:861–76.
  - 154 Huang SH, He L, Zhou Y, et al. *Lactobacillus rhamnosus* GG Suppresses Meningitic *E. coli* K1 Penetration across Human Intestinal Epithelial Cells In Vitro and Protects Neonatal Rats against Experimental Hematogenous Meningitis. *Int J Microbiol* 2009;2009:647862.
  - 155 Winkelstroter LK, De Martinis EC. In vitro protective effect of lactic acid bacteria on *Listeria monocytogenes* adhesion and invasion of Caco-2 cells. *Benef Microbes* 2015;6:535–42.
  - 156 Alemka A, Clyne M, Shanahan F, et al. Probiotic colonization of the adherent mucus layer of HT29MTX12 cells attenuates *Campylobacter jejuni* virulence properties. *Infect Immun* 2010;78:2812–22.
  - 157 Gudina EJ, Rocha V, Teixeira JA, et al. Antimicrobial and antiadhesive properties of a biosurfactant isolated from *Lactobacillus paracasei* ssp. *paracasei* A20. *Lett Appl Microbiol* 2010;50:419–24.
  - 158 Walencka E, Rozalska S, Sadowska B, et al. The influence of *Lactobacillus acidophilus*-derived surfactants on staphylococcal adhesion and biofilm formation. *Folia Microbiol (Praha)* 2008;53:61–6.
  - 159 Sambanthamoorthy K, Feng X, Patel R, et al. Antimicrobial and antibiofilm potential of biosurfactants isolated from *Lactobacilli* against multi-drug-resistant pathogens. *BMC Microbiol* 2014;14:197.
  - 160 Lim SM, Ahn DH. Factors affecting adhesion of lactic acid bacteria to Caco-2 cells and inhibitory effect on infection of *Salmonella typhimurium*. *J Microbiol Biotechnol* 2012;22:1731–9.

- 161 Eom JS, Song J, Choi HS. Protective Effects of a Novel Probiotic Strain of *Lactobacillus plantarum* JSA22 from Traditional Fermented Soybean Food Against Infection by *Salmonella enterica* Serovar Typhimurium. *J Microbiol Biotechnol* 2015;25:479–91.
- 162 Bertaux C, Daelemans D, Meertens L, et al. Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. *Virology* 2007;366:40–50.
- 163 Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in South African women: a nested case-control study. *J Infect Dis* 2005;192:1372–80.
- 164 Watts DH, Fazzari M, Minkoff H, et al. Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. *J Infect Dis* 2005;191:1129–39.
- 165 Cherpès TL, Meyn LA, Krohn MA, et al. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. *Clin Infect Dis* 2003;37:319–25.
- 166 Lehours P, Yilmaz O. Epidemiology of *Helicobacter pylori* infection. *Helicobacter* 2007;12(Suppl 1):1–3.
- 167 Chen X, Liu XM, Tian F, et al. Antagonistic activities of lactobacilli against *Helicobacter pylori* growth and infection in human gastric epithelial cells. *J Food Sci* 2012;77:M9–14.
- 168 Fujimura S, Watanabe A, Kimura K, et al. Probiotic mechanism of *Lactobacillus gasseri* OLL2716 strain against *Helicobacter pylori*. *J Clin Microbiol* 2012;50:1134–6.
- 169 Mukai T, Asasaka T, Sato E, et al. Inhibition of binding of *Helicobacter pylori* to the glycolipid receptors by probiotic *Lactobacillus reuteri*. *FEMS Immunol Med Microbiol* 2002;32:105–10.
- 170 Hatakka K, Holma R, El-Nezami H, et al. The influence of *Lactobacillus rhamnosus* LC705 together with *Propionibacterium freudenreichii* ssp. *shermanii* JS on potentially carcinogenic bacterial activity in human colon. *Int J Food Microbiol* 2008;128:406–10.
- 171 Boyanova L, Stephanova-Kondratenko M, Mitov I. Anti-*Helicobacter pylori* activity of *Lactobacillus delbrueckii* subsp. *bulgaricus* strains: preliminary report. *Lett Appl Microbiol* 2009;48:579–84.
- 172 Coconnier MH, Lievin V, Hemery E, et al. Antagonistic activity against *Helicobacter* infection in vitro and in vivo by the human *Lactobacillus acidophilus* strain LB. *Appl Environ Microbiol* 1998;64:4573–80.
- 173 Cruchet S, Obregon MC, Salazar G, et al. Effect of the ingestion of a dietary product containing *Lactobacillus johnsonii* La1 on *Helicobacter pylori* colonization in children. *Nutrition* 2003;19:716–21.
- 174 Sakamoto I, Igarashi M, Kimura K, et al. Suppressive effect of *Lactobacillus gasseri* OLL 2716 (LG21) on *Helicobacter pylori* infection in humans. *J Antimicrob Chemother* 2001;47:709–10.
- 175 Wang KY, Li SN, Liu CS, et al. Effects of ingesting *Lactobacillus*- and *Bifidobacterium*-containing yogurt in subjects with colonized *Helicobacter pylori*. *Am J Clin Nutr* 2004;80:737–41.
- 176 Aiba Y, Nakano Y, Koga Y, et al. A highly acid-resistant novel strain of *Lactobacillus johnsonii* No. 1088 has antibacterial activity, including that against *Helicobacter pylori*, and inhibits gastrin-mediated acid production in mice. *Microbiologyopen* 2015;4:465–74.
- 177 Compare D, Rocco A, Sgamato C, et al. *Lactobacillus paracasei* F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial. *Dig Liver Dis* 2015;47:273–9.
- 178 Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. *Am J Gastroenterol* 2007;102:2047–56; quiz 57.
- 179 Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. *Aliment Pharmacol Ther* 2006;23:3–10.
- 180 Sanduleanu S, Jonkers D, de Bruine A, et al. Changes in gastric mucosa and luminal environment during acid-suppressive therapy: a review in depth. *Dig Liver Dis* 2001;33:707–19.
- 181 Crittenden R, Saarela M, Mättö J, et al. *Lactobacillus paracasei* subsp. *paracasei* F19: Survival, Ecology and Safety in the Human Intestinal Tract—A Survey of Feeding Studies within the PROBDEMO Project. *Microbial Ecology Health Dis* 2002;14:22–6.
- 182 Tursi A, Brandimarte G, Giorgetti GM, et al. Effect of *Lactobacillus casei* supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure *Helicobacter pylori* infection. *Med Sci Monit* 2004;10:Cr662–6.
- 183 Sykora J, Valeckova K, Amlerova J, et al. Effects of a specially designed fermented milk product containing probiotic *Lactobacillus casei* DN-114 001 and the eradication of *H. pylori* in children: a prospective randomized double-blind study. *J Clin Gastroenterol* 2005;39:692–8.
- 184 Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with *Lactobacillus*- and *Bifidobacterium*-containing yogurt on triple therapy for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther* 2002;16:1669–75.
- 185 Lionetti E, Miniello VL, Castellaneta SP, et al. *Lactobacillus reuteri* therapy to reduce side-effects during anti-*Helicobacter pylori* treatment in children: a randomized placebo controlled trial. *Aliment Pharmacol Ther* 2006;24:1461–8.
- 186 Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for *Helicobacter pylori* eradication. *Helicobacter* 2008;13:261–8.
- 187 Francavilla R, Polimeno L, Demichina A, et al. *Lactobacillus reuteri* strain combination in *Helicobacter pylori* infection: a randomized, double-blind, placebo-controlled study. *J Clin Gastroenterol* 2014;48:407–13.
- 188 Deguchi R, Nakaminami H, Rimbara E, et al. Effect of pretreatment with *Lactobacillus gasseri* OLL2716 on first-line *Helicobacter pylori* eradication therapy. *J Gastroenterol Hepatol* 2012;27:888–92.
- 189 Linsalata M, Russo F, Berloco P, et al. The influence of *Lactobacillus brevis* on ornithine decarboxylase activity and polyamine profiles in *Helicobacter pylori*-infected gastric mucosa. *Helicobacter* 2004;9:165–72.
- 190 Di Cerbo A, Pezzuto F, Palmieri L, et al. Clinical and experimental use of probiotic formulations for management of end-stage renal disease: an update. *Int Urol Nephrol* 2013;5:1569–76.
- 191 Ranganathan N, Ranganathan P, Friedman EA, et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. *Adv Ther* 2010;27:634–47.
- 192 Cook AR. Urease activity in the rumen of sheep and the isolation of ureolytic bacteria. *J Gen Microbiol* 1976;92:32–48.
- 193 Capozzi V, Russo P, Ladero V, et al. Biogenic amines degradation by *Lactobacillus plantarum*: toward a potential application in wine. *Front Microbiol* 2012;3:122.
- 194 Herrero-Fresno A, Martinez N, Sanchez-Llana E, et al. *Lactobacillus casei* strains isolated from cheese reduce biogenic amine accumulation in an experimental model. *Int J Food Microbiol* 2012;157:297–304.
- 195 Murphy C, Murphy S, O'Brien F, et al. Metabolic activity of probiotics-oxalate degradation. *Vet Microbiol* 2009;136:100–7.
- 196 Mogna L, Pane M, Nicola S, et al. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? *J Clin Gastroenterol* 2014;48(Suppl 1):S91–5.
- 197 Campieri C, Campieri M, Bertuzzi V, et al. Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. *Kidney Int* 2001;60:1097–105.
- 198 Freedman GR. Breast-feeding – a guide for the medical profession. *J R Coll Gen Pract* 1981;31:126.
- 199 Delgado S, Arroyo R, Jimenez E, et al. *Staphylococcus epidermidis* strains isolated from breast milk of women suffering infectious mastitis: potential virulence traits and resistance to antibiotics. *BMC Microbiol* 2009;9:82.
- 200 Foxman B, D'Arcy H, Gillespie B, et al. Lactation mastitis: occurrence and medical management among 946 breastfeeding women in the United States. *Am J Epidemiol* 2002;155:103–14.
- 201 WHO. Mastitis: causes and management. 2000 /entity/maternal\_child\_adolescent/documents/fch\_cah\_00\_13/en/index.html
- 202 Arroyo R, Martin V, Maldonado A, et al. Treatment of infectious mastitis during lactation: antibiotics versus oral administration of *Lactobacilli* isolated from breast milk. *Clin Infect Dis* 2010;50:1551–8.
- 203 Jimenez E, Fernandez L, Maldonado A, et al. Oral administration of *Lactobacillus* strains isolated from breast milk as an alternative for the treatment of infectious mastitis during lactation. *Appl Environ Microbiol* 2008;74:4650–5.
- 204 Tuomola E, Crittenden R, Playne M, et al. Quality assurance criteria for probiotic bacteria. *Am J Clin Nutr* 2001;73(2 Suppl):393s–8s.
- 205 Iwabuchi N, Yonezawa S, Odamaki T, et al. Immunomodulating and anti-infective effects of a novel strain of *Lactobacillus paracasei* that strongly induces interleukin-12. *FEMS Immunol Med Microbiol* 2012;66:230–9.
- 206 Soltan Dallal MM, Yazdi MH, Holakuyee M, et al. *Lactobacillus casei* ssp. *casei* induced Th1 cytokine profile and natural killer cells activity in invasive ductal carcinoma bearing mice. *Iran J Allergy Asthma Immunol* 2012;11:183–9.
- 207 Yesilova Y, Calka O, Akdeniz N, et al. Effect of probiotics on the treatment of children with atopic dermatitis. *Ann Dermatol* 2012;24:189–93.
- 208 Taverniti V, Minuzzo M, Arioli S, et al. In vitro functional and immunomodulatory properties of the *Lactobacillus helveticus* MIMLh5-*Streptococcus salivarius* ST3 association that are relevant to the development of a pharyngeal probiotic product. *Appl Environ Microbiol* 2012;78:4209–16.
- 209 Ghadimi D, de Vrese M, Heller KJ, et al. Lactic acid bacteria enhance autophagic ability of mononuclear phagocytes by increasing Th1 autophagy-promoting cytokine (IFN- $\gamma$ ) and nitric oxide (NO) levels and reducing Th2 autophagy-restraining cytokines (IL-4 and IL-13) in response to *Mycobacterium tuberculosis* antigen. *Int Immunopharmacol* 2010;10:694–706.
- 210 Ivory K, Chambers SJ, Pin C, et al. Oral delivery of *Lactobacillus casei* Shirota modifies allergen-induced immune responses in allergic rhinitis. *Clin Exp Allergy* 2008;38:1282–9.
- 211 Osman N, Adawi D, Ahme S, et al. Endotoxin- and D-galactosamine-induced liver injury improved by the administration of *Lactobacillus*, *Bifidobacterium* and blueberry. *Dig Liver Dis* 2007;39:849–56.
- 212 Machairas N, Pistiki A, Droggiti DI, et al. Pre-treatment with probiotics prolongs survival after experimental infection by multidrug-resistant *Pseudomonas*

- aeruginosa in rodents: an effect on sepsis-induced immunosuppression. *Int J Antimicrob Agents* 2015;45:376–84.
- 213 Carasi P, Racedo SM, Jacquot C, *et al.* Impact of kefir derived *Lactobacillus kefir* on the mucosal immune response and gut microbiota. *J Immunol Res* 2015;2015:361604.
  - 214 Yoda K, He F, Miyazawa K, *et al.* Orally administered heat-killed *Lactobacillus gasseri* TMC0356 alters respiratory immune responses and intestinal microbiota of diet-induced obese mice. *J Appl Microbiol* 2012;113:155–62.
  - 215 Hougee S, Vriesema AJ, Wijering SC, *et al.* Oral treatment with probiotics reduces allergic symptoms in ovalbumin-sensitized mice: a bacterial strain comparative study. *Int Arch Allergy Immunol* 2010;151:107–17.
  - 216 Wang MF, Lin HC, Wang YY, *et al.* Treatment of perennial allergic rhinitis with lactic acid bacteria. *Pediatr Allergy Immunol* 2004;15:152–8.
  - 217 Chou LS, Weimer B. Isolation and characterization of acid- and bile-tolerant isolates from strains of *Lactobacillus acidophilus*. *J Dairy Sci* 1999;82:23–31.
  - 218 Macfarlane S, Furrie E, Cummings JH, *et al.* Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. *Clin Infect Dis* 2004;38:1690–9.
  - 219 Li CY, Lin HC, Lai CH, *et al.* Immunomodulatory effects of *Lactobacillus* and *Bifidobacterium* on both murine and human mitogen-activated T cells. *Int Arch Allergy Immunol* 2011;156:128–36.
  - 220 Kailasapathy K, Chin J. Survival and therapeutic potential of probiotic organisms with reference to *Lactobacillus acidophilus* and *Bifidobacterium* spp. *Immunol Cell Biol* 2000;78:80–8.
  - 221 Meydani SN, Ha WK. Immunologic effects of yogurt. *Am J Clin Nutr* 2000;71:861–72.
  - 222 Diop L, Guillou S, Durand H. Probiotic food supplement reduces stress-induced gastrointestinal symptoms in volunteers: a double-blind, placebo-controlled, randomized trial. *Nutr Res* 2008;28:1–5.
  - 223 Iemoli E, Trabattini D, Parisotto S, *et al.* Probiotics reduce gut microbial translocation and improve adult atopic dermatitis. *J Clin Gastroenterol* 2012;46 (Suppl):S33–40.
  - 224 Shinkai S, Toba M, Saito T, *et al.* Immunoprotective effects of oral intake of heat-killed *Lactobacillus pentosus* strain b240 in elderly adults: a randomised, double-blind, placebo-controlled trial. *Br J Nutr* 2013;109:1856–65.
  - 225 Inoue Y, Kambara T, Murata N, *et al.* Effects of oral administration of *Lactobacillus acidophilus* L-92 on the symptoms and serum cytokines of atopic dermatitis in Japanese adults: a double-blind, randomized, clinical trial. *Int Arch Allergy Immunol* 2014;165:247–54.
  - 226 Linskens RK, Huijsdens XW, Savelkoul PH, *et al.* The bacterial flora in inflammatory bowel disease: current insights in pathogenesis and the influence of antibiotics and probiotics. *Scand J Gastroenterol Suppl* 2001;36:(234):29–40.
  - 227 Feher J, Kovacs I, Pacella E, *et al.* [Correlation of the microbiota and intestinal mucosa in the pathophysiology and treatment of irritable bowel, irritable eye, and irritable mind syndrome]. *Orv Hetil* 2014;155:1454–60.
  - 228 Mizoguchi A. Animal models of inflammatory bowel disease. *Prog Mol Biol Transl Sci* 2012;105:263–320.
  - 229 Scaldaferrri F, Gerardi V, Lopetuso LR, *et al.* Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. *BioMed Res Int* 2013;2013:435268.
  - 230 Gionchetti P, Rizzello F, Venturi A, *et al.* Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. *Gastroenterology* 2000;119:305–9.
  - 231 Sakai T, Kubota H, Gawad A, *et al.* Effect of fermented milk containing *Lactobacillus casei* strain Shirota on constipation-related symptoms and haemorrhoids in women during puerperium. *Benef Microbes* 2015;6:253–62.
  - 232 Higashikawa F, Noda M, Awaya T, *et al.* Improvement of constipation and liver function by plant-derived lactic acid bacteria: a double-blind, randomized trial. *Nutrition (Burbank, Los Angeles County, Calif.)* 2010;26:367–74.
  - 233 Venturi A, Gionchetti P, Rizzello F, *et al.* Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. *Aliment Pharmacol Ther* 1999;13:1103–8.
  - 234 Ishibashi N, Yaeshima T, Hayasawa H. *Bifidobacteria*: Their Significance in Human Intestinal Health. *Mal J Nutr* 1997;3:149–59.
  - 235 Corcoran BM, Stanton C, Fitzgerald GF, *et al.* Growth of probiotic *Lactobacilli* in the presence of oleic acid enhances subsequent survival in gastric juice. *Microbiology* 2007;153(Pt 1):291–9.
  - 236 Kilic GB, Karahan AG. Identification of lactic acid bacteria isolated from the fecal samples of healthy humans and patients with dyspepsia, and determination of their pH, bile, and antibiotic tolerance properties. *J Mol Microbiol Biotechnol* 2010;18:220–9.
  - 237 Marteau P, Pochart P, Bouhnik Y, *et al.* [Survival of *Lactobacillus acidophilus* and *Bifidobacterium* sp. in the small intestine following ingestion in fermented milk. A rational basis for the use of probiotics in man]. *Gastroenterol Clin Biol Gastroenterologie* 1992;16:25–8.
  - 238 Wang R, Chen S, Jin J, *et al.* Survival of *Lactobacillus casei* strain Shirota in the intestines of healthy Chinese adults. *Microbiol Immunol* 2015;59:268–76.
  - 239 Piano MD, Carmagnola S, Ballare M, *et al.* Comparison of the kinetics of intestinal colonization by associating 5 probiotic bacteria assumed either in a microencapsulated or in a traditional, uncoated form. *J Clin Gastroenterol* 2012;46 (Suppl):S85–92.
  - 240 Del Piano M, Carmagnola S, Andorno S, *et al.* Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in comparison with the same uncoated strains. *J Clin Gastroenterol* 2010;44(Suppl 1):S42–6.
  - 241 Szymanski H, Chmielarczyk A, Strus M, *et al.* Colonisation of the gastrointestinal tract by probiotic *L. rhamnosus* strains in acute diarrhoea in children. *Dig Liver Dis* 2006;38(Suppl 2):S274–6.
  - 242 Visich KL, Yeo TP. The prophylactic use of probiotics in the prevention of radiation therapy-induced. *Clin J Oncol Nurs* 2010;14:467–73.
  - 243 Bergogne-Berezin E. Treatment and prevention of antibiotic associated diarrhea. *Int J Antimicrob Agents* 2000;16:521–6.
  - 244 Eser A, Thalhammer F, Burghuber F, *et al.* [Probiotics for the prevention of antibiotic-induced diarrhea]. *Z Gastroenterol* 2012;50:1089–95.
  - 245 Kelly CP, LaMont JT. *Clostridium difficile* infection. *Annu Rev Med* 1998;49:375–90.
  - 246 Kelly CP, Pothoulakis C, LaMont JT. *Clostridium difficile* colitis. *N Engl J Med* 1994;330:257–62.
  - 247 Boonma P, Spinler JK, Venable SF, *et al.* *Lactobacillus rhamnosus* L34 and *Lactobacillus casei* L39 suppress *Clostridium difficile*-induced IL-8 production by colonic epithelial cells. *BMC Microbiol* 2014;14:177.
  - 248 Yun B, Oh S, Griffiths MW. *Lactobacillus acidophilus* modulates the virulence of *Clostridium difficile*. *J Dairy Sci* 2014;97:4745–58.
  - 249 Dietrich CG, Kottmann T, Alavi M. Commercially available probiotic drinks containing *Lactobacillus casei* DN-114001 reduce antibiotic-associated diarrhea. *World J Gastroenterol* 2014;20:15837–44.
  - 250 Shavakhi A, Tabesh E, Yaghoutkar A, *et al.* The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for *Helicobacter pylori* infection: a randomized placebo-controlled triple-blind study. *Helicobacter* 2013;18:280–4.
  - 251 Dinleyici EC, Dalgic N, Guven S, *et al.* The effect of a multispecies synbiotic mixture on the duration of diarrhea and length of hospital stay in children with acute diarrhea in Turkey: single blinded randomized study. *Eur J Pediatr* 2013; 172:459–64.
  - 252 Allen SJ, Wareham K, Bradley C, *et al.* A multicentre randomised controlled trial evaluating *Lactobacilli* and *Bifidobacteria* in the prevention of antibiotic-associated diarrhoea in older people admitted to hospital: the PLACIDE study protocol. *BMC Infect Dis* 2012;12:108.
  - 253 Vandenplas Y, De Hert SG, group PR-s. Randomised clinical trial: the synbiotic food supplement Probiotal vs. placebo for acute gastroenteritis in children. *Aliment Pharmacol Ther* 2011;34:862–7.
  - 254 Grandy G, Medina M, Soria R, *et al.* Probiotics in the treatment of acute rotavirus diarrhoea. A randomized, double-blind, controlled trial using two different probiotic preparations in Bolivian children. *BMC Infect Dis* 2010; 10:253.
  - 255 Fang SB, Lee HC, Hu JJ, *et al.* Dose-dependent effect of *Lactobacillus rhamnosus* on quantitative reduction of faecal rotavirus shedding in children. *J Trop Pediatr* 2009;55:297–301.
  - 256 Ruszczynski M, Radzikowski A, Szajewska H. Clinical trial: effectiveness of *Lactobacillus rhamnosus* (strains E/N, Oxy and Pen) in the prevention of antibiotic-associated diarrhoea in children. *Aliment Pharmacol Ther* 2008;28:154–61.
  - 257 Lievin-Le Moal V, Sarrazin-Davila LE, Servin AL. An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of *Lactobacillus acidophilus* strain LB against nonrotavirus diarrhea. *Pediatrics* 2007;120:e795–803.
  - 258 Szymanski H, Pejcz J, Jawien M, *et al.* Treatment of acute infectious diarrhoea in infants and children with a mixture of three *Lactobacillus rhamnosus* strains—a randomized, double-blind, placebo-controlled trial. *Aliment Pharmacol Ther* 2006;23:247–53.
  - 259 Sarker SA, Sultana S, Fuchs GJ, *et al.* *Lactobacillus paracasei* strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. *Pediatrics* 2005;116:e221–8.
  - 260 Gaon D, Garcia H, Winter L, *et al.* Effect of *Lactobacillus* strains and *Saccharomyces boulardii* on persistent diarrhea in children. *Medicina (B Aires)* 2003;63:293–8.
  - 261 Rosenfeldt V, Michaelsen KF, Jakobsen M, *et al.* Effect of probiotic *Lactobacillus* strains on acute diarrhea in a cohort of nonhospitalized children attending day-care centers. *Pediatr Infect Dis J* 2002;21:417–19.
  - 262 Gaon D, Garmendia C, Murriello NO, *et al.* Effect of *Lactobacillus* strains (*L. casei* and *L. Acidophilus* Strains cerela) on bacterial overgrowth-related chronic diarrhea. *Medicina (B Aires)* 2002;62:159–63.
  - 263 Shornikova AV, Casas IA, Isolauri E, *et al.* *Lactobacillus reuteri* as a therapeutic agent in acute diarrhea in young children. *J Pediatr Gastroenterol Nutr* 1997;24:399–404.
  - 264 Ranney RR. Classification of periodontal diseases. *Periodontol* 2000 1993;2:13–25.



- 265 Soder B, Andersson LC, Meurman JH, *et al.* Unique database study linking gingival inflammation and smoking in carcinogenesis. *Philos Trans R Soc Lond B Biol Sci* 2015;370:20140041.
- 266 Listgarten MA. Pathogenesis of periodontitis. *J Clin Periodontol* 1986;13:418–30.
- 267 Golub LM, Ryan ME, Williams RC. Modulation of the host response in the treatment of periodontitis. *Dent Today* 1998;17:102–6, 08–9.
- 268 Adams D, Addy M. Mouthrinses. *Adv Dent Res* 1994;8:291–301.
- 269 Eley BM. Antibacterial agents in the control of supragingival plaque—a review. *Br Dent J* 1999;186:286–96.
- 270 Van Leeuwen MP, Slot DE, Van der Weijden GA. Essential oils compared to chlorhexidine with respect to plaque and parameters of gingival inflammation: a systematic review. *J Periodontol* 2011;82:174–94.
- 271 Flotra L, Gjermo P, Rolla G, *et al.* Side effects of chlorhexidine mouth washes. *Scand J Dent Res* 1971;79:119–25.
- 272 Samot J, Badet C. Antibacterial activity of probiotic candidates for oral health. *Anaerobe* 2013;19:34–8.
- 273 Loe H. The gingival index, the plaque index and the retention index systems. *J Periodontol* 1967;38:Suppl:610–16.
- 274 Shimauchi H, Mayanagi G, Nakaya S, *et al.* Improvement of periodontal condition by probiotics with *Lactobacillus salivarius* WB21: a randomized, double-blind, placebo-controlled study. *J Clin Periodontol* 2008;35:897–905.
- 275 Twetman S, Derawi B, Keller M, *et al.* Short-term effect of chewing gums containing probiotic *Lactobacillus reuteri* on the levels of inflammatory mediators in gingival crevicular fluid. *Acta Odontol Scand* 2009;67:19–24.
- 276 Saha S, Tomaro-Duchesneau C, Rodes L, *et al.* Investigation of probiotic bacteria as dental caries and periodontal disease biotherapeutics. *Benef Microbes* 2014;5:447–60.
- 277 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998; 15:539–53.
- 278 Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol* 2011;11:98–107.
- 279 Donath MY, Ehses JA, Maedler K, *et al.* Mechanisms of beta-cell death in type 2 diabetes. *Diabetes* 2005;54(Suppl 2):S108–13.
- 280 Yang H, Youm YH, Vandanmagsar B, *et al.* Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. *J Immunol* 2010;185:1836–45.
- 281 Panwar H, Calderwood D, Grant IR, *et al.* *Lactobacillus* strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential. *Eur J Nutr* 2014;53:1465–74.
- 282 Asemi Z, Zare Z, Shakeri H, *et al.* Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes. *Ann Nutr Metab* 2013;63:1–9.
- 283 Hayami T, Pickarski M, Zhuo Y, *et al.* Characterization of articular cartilage and subchondral bone changes in the rat. *Bone* 2006;38:234–43.
- 284 Benito MJ, Veale DJ, Fitzgerald O, *et al.* Synovial tissue inflammation in early and late osteoarthritis. *Ann Rheum Dis* 2005;64:1263–7.
- 285 Kano H, Kaneko T, Kaminogawa S. Oral intake of *Lactobacillus delbrueckii* subsp. *bulgaricus* OLL1073R-1 prevents collagen-induced arthritis in mice. *J Food Prot* 2002;65:153–60.
- 286 So JS, Kwon HK, Lee CG, *et al.* *Lactobacillus casei* suppresses experimental arthritis by down-regulating T helper. *Mol Immunol* 2008;45:2690–9.
- 287 So JS, Song MK, Kwon HK, *et al.* *Lactobacillus casei* enhances type II collagen/glucosamine-mediated suppression of. *Life Sci* 2011;88:358–66.
- 288 Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. *BMC Complement Altern Med* 2010;10:1.
- 289 Wu CC, Weng WL, Lai WL, *et al.* Effect of *Lactobacillus plantarum* Strain K21 on High-Fat Diet-Fed Obese Mice. *Evid Based Complement Alternat Med* 2015;2015:391767.
- 290 Jeong JJ, Kim KA, Ahn YT, *et al.* Probiotic mixture KF attenuates age-dependent memory deficit and lipidemia in Fischer 344 rats. *J Microbiol Biotechnol* 2015;25:1532–6.
- 291 [No authors listed]. Randomized controlled study of probiotics containing *Lactobacillus casei* (Shirota strain) for prevention of ventilator-associated pneumonia. *J Med Assoc Thai* 2015;98:253–9.
- 292 Oláh A, Belágyi T, Pótó L, *et al.* Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. *Hepatogastroenterology* 2007;54:590–4.
- 293 Besselink MG, van Santvoort HC, Buskens E, *et al.* Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised. *Lancet* 2008;371:651–9.
- 294 Annibale B, Maconi G, Lahner E, *et al.* Efficacy of *Lactobacillus paracasei* sub. *paracasei* F19 on abdominal symptoms in patients with symptomatic uncomplicated diverticular disease: a pilot study. *Minerva Gastroenterol Dietol* 2011;57:13–22.
- 295 Bajaj JS, Heuman DM, Hylemon PB, *et al.* Randomised clinical trial: *Lactobacillus* GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. *Aliment Pharmacol Ther* 2014;39:1113–25.
- 296 Zein EF, Karaa S, Chemaly A, *et al.* [*Lactobacillus rhamnosus* septicemia in a diabetic patient associated with probiotic use: a case report]. *Ann Biol Clin (Paris)* 2008;66:195–8.
- 297 Moudden MK, Boukhira A, Sarret D, *et al.* [Septicaemia due to *Lactobacillus jensenii*: bacteriological diagnostic orientation]. *Annales de biologie clinique* 2007;65:299–302.
- 298 Jureen R, Sondenaa K, Hoiby EA, *et al.* *Lactobacillus rhamnosus* septicemia in a patient with a graft in the inferior vena cava. *Scand J Infect Dis* 2002;34:135–6.
- 299 Farina C, Arosio M, Mangia M, *et al.* *Lactobacillus casei* subsp. *rhamnosus* sepsis in a patient with ulcerative colitis. *J Clin Gastroenterol* 2001;33:251–2.
- 300 Land MH, Rouster-Stevens K, Woods CR, *et al.* *Lactobacillus* sepsis associated with probiotic therapy. *Pediatrics* 2005;115:178–81.
- 301 Kochan P, Chmielarczyk A, Szymaniak L, *et al.* *Lactobacillus rhamnosus* administration causes sepsis in a cardiosurgical patient—is the time right to revise probiotic safety guidelines? *Clin Microbiol Infect* 2011;17:1589–92.
- 302 Fradiani PA, Petrucca A, Ascenzioni F, *et al.* Endocarditis caused by *Lactobacillus jensenii* in an immunocompetent patient. *J Med Microbiol* 2010;59(Pt 5):607–9.
- 303 Schmidt V, Wolter M, Lenschow U, *et al.* [*Lactobacillus paracasei* endocarditis in an 18-year-old patient with trisomy 21 atrioventricular septal defect and Eisenmenger complex: therapeutic problems]. *Klin Padiatr* 2001;213:35–8.
- 304 Suarez-Garcia I, Sanchez-Garcia A, Soler L, *et al.* *Lactobacillus jensenii* bacteremia and endocarditis after dilatation and curettage: case report and literature review. *Infection* 2012;40:219–22.
- 305 Chong Y, Lim HS, Lee SY, *et al.* *Lactobacillus casei* subspecies *casei* endocarditis—a case report. *Yonsei Med J* 1991;32:69–73.
- 306 Arpi M, Vancanney M, Swings J, *et al.* Six cases of *Lactobacillus* bacteraemia: identification of organisms and antibiotic susceptibility and therapy. *Scand J Infect Dis* 2003;35:404–8.
- 307 Bar W, Euteneuer B, Schuster S. [Bacteremia caused by *Lactobacillus plantarum* in endocarditis lenta]. *Immun Infekt* 1987;15:173–4.
- 308 Carretto E, Barbarini D, Marzani FC, *et al.* Catheter-related bacteremia due to *Lactobacillus rhamnosus* in a single-lung transplant recipient. *Scand J Infect Dis* 2001;33:780–2.
- 309 Chazan B, Raz R, Shental Y, *et al.* Bacteremia and pyelonephritis caused by *Lactobacillus jensenii* in a patient with urolithiasis. *Isr Med Assoc J The Israel* 2008;10:164–5.
- 310 De Groote MA, Frank DN, Dowell E, *et al.* *Lactobacillus rhamnosus* GG bacteremia associated with probiotic use in a child with short gut syndrome. *Pediatr Infect Dis J* 2005;24:278–80.
- 311 Duprey KM, McCrea L, Rabinowitch BL, *et al.* Pyelonephritis and Bacteremia from *Lactobacillus delbrueckii*. *Case Rep Infect Dis* 2012;2012:745743.
- 312 Gouriet F, Million M, Henri M, *et al.* *Lactobacillus rhamnosus* bacteremia: an emerging clinical entity. *Eur J Clin Microbiol Infect Dis* 2012;31:2469–80.
- 313 Kunz AN, Noel JM, Fairchok MP. Two cases of *Lactobacillus* bacteremia during probiotic treatment of short gut syndrome. *J Pediatr Gastroenterol Nutr* 2004;38:457–8.
- 314 Majcher-Peszyńska J, Heine W, Richter I, *et al.* [Persistent *Lactobacillus casei* subspecies *rhamnosus* bacteremia in a 14 year old girl with acute myeloid leukemia. A case report]. *Klin Padiatr* 1999;211:53–6.
- 315 Mehta A, Rangarajan S, Borate U. A cautionary tale for probiotic use in hematopoietic SCT patients-*Lactobacillus acidophilus* sepsis in a patient with mantle cell lymphoma undergoing hematopoietic SCT. *Bone Marrow Transplant* 2013;46:1–2.
- 316 Notario R, Leardini N, Borda N, *et al.* [Hepatic abscess and bacteremia due to *Lactobacillus rhamnosus*]. *Rev Argent Microbiol* 2003;35:100–1.
- 317 Salminen MK, Rautelin H, Tynkkynen S, *et al.* *Lactobacillus* bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. *rhamnosus* GG. *Clin Infect Dis* 2004;38:62–9.
- 318 Suarez-Quiroz M, Gonzalez-Rios O, Barel M, *et al.* Effect of the post-harvest processing procedure on OTA occurrence in artificially contaminated coffee. *Int J Food Microbiol* 2005;103:339–45.
- 319 Tommasi C, Equitani F, Masala M, *et al.* Diagnostic difficulties of *Lactobacillus casei* bacteraemia in immunocompetent patients: a case report. *J Med Case Rep* 2008;2:315.
- 320 Robin F, Paillard C, Marchand H, *et al.* *Lactobacillus rhamnosus* meningitis following recurrent episodes of bacteremia in a child undergoing allogeneic hematopoietic stem cell transplantation. *J Clin Microbiol* 2010;48:4317–19.
- 321 Husni RN, Gordon SM, Washington JA, *et al.* *Lactobacillus* bacteremia and endocarditis: review of 45 cases. *Clin Infect Dis* 1997;25:1048–55.
- 322 Simkins J, Kaltsas A, Currie BP. Investigation of inpatient probiotic use at an academic medical center. *Int J Infect Dis* 2013;17:e321–4.
- 323 Burns D, Hurst JR, Hopkins S, *et al.* Purpura fulminans associated with *Lactobacillus paracasei* liver abscess. *Anaesth Intensive Care* 2007;35:121–3.



- 324 Cukovic-Cavka S, Likic R, Francetic I, *et al.* Lactobacillus acidophilus as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease. *Digestion* 2006;73:107–10.
- 325 Rogasi PG, Vigano S, Pecile P, *et al.* Lactobacillus casei pneumonia and sepsis in a patient with AIDS. Case report and review of the literature. *Ann Ital Med Int* 1998;13:180–2.
- 326 Dickgiesser U, Weiss N, Fritsche D. Lactobacillus gasseri as the cause of septic urinary infection. *Infection* 1984;12:14–16.
- 327 Russo A, Angeletti S, Lorino G, *et al.* A case of Lactobacillus casei bacteraemia associated with aortic dissection: is there a link? *New Microbiol* 2010;33:175–8.
- 328 Bartalesi F, Veloci S, Baragli F, *et al.* Successful tigecycline lock therapy in a Lactobacillus rhamnosus catheter-related bloodstream infection. *Infection* 2012;40:331–4.
- 329 Wolz M, Schaefer J. "Swiss cheese-like" brain due to Lactobacillus rhamnosus. *Neurology* 2008;70:979.
- 330 Franko B, Vaillant M, Recule C, *et al.* Lactobacillus paracasei endocarditis in a consumer of probiotics. *Med Mal Infect* 2013;43:171–3.
- 331 Thomas CM, Versalovic J. Probiotics-host communication: Modulation of signaling pathways in the intestine. *Gut Microbes* 2010;1:148–63.
- 332 Di Cerbo A, Palmieri B. Lactobacillus Paracasei subsp. Paracasei F19; a farmacogenomic and clinical update. *Nutr Hosp* 2013;28:1842–50.
- 333 Morelli L, Campominosi E. Genetic stability of Lactobacillus paracasei subsp. paracasei F19. *Microb Ecol Health Dis* 2002;14:14–16.
- 334 Charteris WP, Kelly PM, Morelli L, *et al.* Antibiotic susceptibility of potentially probiotic Lactobacillus species. *J Food Prot* 1998;61:1636–43.
- 335 Zarazaga M, Saenz Y, Portillo A, *et al.* In vitro activities of ketolide HMR3647, macrolides, and other antibiotics against Lactobacillus, Leuconostoc, and Pediococcus isolates. *Antimicrob Agents Chemother* 1999;43:3039–41.
- 336 Danielsen M, Wind A. Susceptibility of Lactobacillus spp. to antimicrobial agents. *Int J Food Microbiol* 2003;82:1–11.
- 337 Mattila-Sandholm T, Jaana M, Saarela M. Lactic acid bacteria with health claims—interactions and interference with gastrointestinal flora. *Int Dairy J* 2013;9:25–35.
- 338 Liu H, Gao Y, Yu LR, *et al.* Inhibition of Staphylococcus aureus by lysostaphin-expressing lactobacillus plantarum WCFS1 in a modified genital tract secretion medium. *Appl Environ Microbiol* 2011;77:8500–8.